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RIASSUNTO 
 
Le patologie ematologiche sono disordini clonali generati dalla trasformazione 
neoplastica di cellule progenitrici ematopoietiche. La progressione leucemica delle 
cellule tumorali è indotta da eventi intrinseci come l’attivazione di oncogeni e la 
perdita di geni soppressori. Sebbene i difetti cellulari intrinseci causativi della 
trasformazione neoplastica siano stati studiati estensivamente nel campo delle 
leucemie, i fattori del microambiente midollare coinvolti negli eventi della 
tumorigenesi non sono stati ancora chiaramente definiti. In particolare, le cellule 
staminali ematopoietiche risiedono nel midollo osseo ed interagiscono con un 
microambiente altamente organizzato composto da diverse sotto-popolazioni di 
cellule stromali e una matrice extracellulare ricca di fibronectina, collagene e vari 
proteoglicani. L’interazione tra le cellule staminali e il microambiente midollare è 
critica nella regolazione dei processi di migrazione, “self-renewal”, proliferazione e 
differenziazione cellulare. Similmente alla loro controparte normale, i progenitori 
cellulari ematopoietici leucemici restano dipendenti dai segnali provenienti dal 
microambiente per sopravvivere e proliferare durante la progressione neoplastica. In 
particolare, la cellula staminale ematopoietica normale o tumorale, risiede all’interno 
di aree del midollo osseo altamente specializzate, definite nicchie del microambiente 
midollare: la nicchia endosteale (o osteoblastica) e la nicchia vascolare. La nicchia 
osteoblastica, localizzata nella superficie interna della cavità dell’osso, fornisce 
stimoli di quiescenza per le cellule staminali long-term (cosi definite poiché cellule 
indifferenziate con elevata capacità di generare cellule a loro volta immature e 
toti/multi potenti a lungo termine) coinvolte nell’emopoiesi. Invece, le nicchie 
vascolari, che consistono in cellule sinusoidali endoteliali ricoprenti il vaso sanguigno, 
promuovono la proliferazione e la differenziazione di cellule ematopoietiche staminali 
short-term (ovvero cellule staminali più differenziate con capacità di generare cellule 
a loro volta immature a breve termine). L’interazione delle cellule stromali e della 
matrice extracellulare con i blasti leucemici controlla anche i segnali anti-apoptotici 
che contribuiscono alla progressione neoplastica e alla persistenza del clone 
neoplastico residuo dopo trattamento.  
La LMC è una neoplasia mieloproliferativa che colpisce le cellule staminali del 
midollo emopoietico da cui derivano i globuli bianchi (leucociti), le piastrine ed i 
globuli rossi. Alla base della malattia c’è un evento genetico che porta alla 
formazione del cromosoma Philadelphia (Ph), così chiamato dal nome della città in 
cui è stato scoperto nel 1960. 
La malattia rappresenta circa il 15% di tutti i casi di leucemia e la prevalenza è 
stimata intorno a uno-due casi ogni 100.000 persone/anno. L’età media alla diagnosi 
è circa 60 anni e raramente inferiore a 20 anni.  
Un ruolo centrale nella patogenesi della CML è la formzione del gene di fusione tra il 
gene “Abelson murine leukemia” (ABL) sul cromosoma 9 e il gene “breakpoint cluster 
region” (BCR) sul cromosoma 22. Il gene di fusione BCR-ABL  codifica per  
l’oncoproteina BCR-ABL.  
Il gene ABL appartiene alla categoria delle tirosino-chinasi (TK), enzimi che 
fosforilano i substrati a livello di residui di tirosina. mediante la sua attività TKI, abl è 
in grado di attivare una “cascata” di altre proteine intracellulari che innescano i 
meccanismi della proliferazione cellulare.  
Nella t(9;22) il gene ABL viene pressoché interamente traslocato sul cromosoma 22 
e la proteina ibrida derivata dal gene ibrido BCR-ABL mantiene una attività TK 
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aumentata e non più sottoposta a normali meccanismi di controllo. Da ciò deriva il 
potenziale leucemogenico della proteina ibrida, per le conseguenti interferenze a 
livello dell’attività proliferativa della cellula neoplastica, dei meccanismi di adesione e 
della responsività ai fattori regolanti la proliferazione, e dei meccanismi di morte 
cellulare (apoptosi). Quindi la proteina ibrida BCR-ABL è una TK costitutivamente 
attiva che promuove la crescita e la replicazione cellulare attivando una serie di 
cascate a valle come RAS, RAF, la JUN chinasi, MYC e STAT.  
Nella storia naturale della LMC si distinguono tre fasi successive: 
Fase cronica  
I pazienti presentano un elevato numero di globuli bianchi in tutti gli stadi di 
maturazione e, meno del 10% di cellule indifferenziate (definite blastiche), nel 
sangue periferico e nel midollo osseo. Nella evoluzione naturale della LMC la fase 
cronica può durare 5 o 6 anni prima di progredire verso la fase accelerata.  
Fase accelerata  
La fase accelerata è una fase intermedia nella storia della malattia in cui si comincia 
ad evidenziare una certa resistenza alle terapie. È caratterizzata dalla presenza nel 
sangue periferico o nel midollo osseo del 10-30% di cellule indifferenziate. I sintomi 
peggiorano e comprendono febbre di origine sconosciuta, dolore osseo, sintomi 
correlati all'ingrossamento della milza o del fegato, come nausea e dolori addominali. 
Possono manifestarsi diminuzione delle piastrine e anemia progressiva. Si 
osservano anche nuove e multiple anomalie cromosomiche. La fase accelerata 
naturalemnete dura in media da 6 a 9 mesi.  
L'Organizzazione Mondiale della Sanità (OMS) definisce questo stadio della LMC in 
base alla presenza di uno o più dei seguenti condizioni:  
a) percentuale di blasti (cellule immature) nel midollo osseo o nel sangue 
periferico pari al 10-19%; 
b) percentuale di basofili nel sangue periferico pari o superiore al 20%; 
c) conta piastrinica persistentemente inferiore a 100 x 109/l o superiore a 
>1000 x 109/l, indipendentemente dalla terapia;  
d) aumento di dimensioni della milza e aumento del numero dei globuli 
bianchi nel sangue periferico, indipendentemente dalla terapia;  
e) segni di evoluzione clonale (cioè comparsa di un'anomalia genetica 
aggiuntiva che non era presente al momento della diagnosi). Le 
alterazioni citogenetiche associate più frequentemente all'evoluzione 
della malattia sono un cromosoma Philadelphia aggiuntivo, la trisomia 8 
(presenza di tre copie del cromosoma 8 invece di due), l'isocromosoma 
17q (cromosoma anomalo formato dalla duplicazione di uno dei due 
bracci del cromosoma, che sostituisce l'altro) e la trisomia 19. 
Crisi blastica  
In circa il 25% dei pazienti la malattia passa dalla fase cronica direttamente alla fase 
blastica, saltando la fase accelerata.  
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La crisi blastica, che rappresenta lo stadio terminale della malattia, è caratterizzata 
dalla presenza di oltre il 30% di blasti nel sangue periferico o nel midollo osseo e da 
un aumento dei sintomi legato al progressivo e grave scompenso della funzione 
midollare: facile affaticabilità legata alla anemia, complicanze emorragiche legate alla 
carenza di piastrine e complicanze infettive legate alla progressiva 
riduzione/scomparsa di globuli bianchi maturi. 
La crisi blastica è una situazione molto difficile e non esiste una forma di terapia 
veramente soddisfacente, incluso il trapianto. I nuovi farmaci, in una percentuale 
minoritaria di pazienti, sono in grado di riportare condizioni di stabilità (che spesso 
non sono durature). 
 
L'OMS definisce la crisi blastica in base alla presenza di uno o più dei seguenti 
condizioni:  
a. percentuale di blasti nel midollo osseo o nel sangue periferico pari o 
superiore al 20%;  
b. presenza di ampi aggregati o gruppi di blasti alla biopsia del midollo 
osseo;  
c. sviluppo di blasti al di fuori del midollo osseo. In circa un terzo dei 
pazienti i blasti hanno un aspetto linfoide (cioè somigliante a quello dei 
progenitori dei linfociti), mentre nei due terzi rimanenti hanno un 
aspetto mieloide (cioè somigliante a quello dei progenitori di tutti gli altri 
globuli bianchi) o indifferenziato (cioè senza caratteristiche distintive 
particolari). Le sedi extramidollari più frequentemente interessate dalla 
BC sono la pelle, i linfonodi, la milza, le ossa e il sistema nervoso 
centrale, ma la fase blastica può coinvolgere qualunque altro distretto 
corporeo. 
La malattia viene generalmente diagnosticata in fase cronica, spesso in occasione di 
esami di routine quando il paziente è asintomatico. Molto raramente alla diagnosi il 
paziente si presenta in fase accelerata o blastica. 
Fino a poco più di dieci anni fa, la terapia per la LMC era limitata ad alcuni agenti 
terapeutici non specifici come l’agente alchilante ciclo cellulare non-specifico 
busulfan, idrossiurea ed interferone alfa. 
L’inibitore della sintesi del DNA l idrossiurea fu introdotto negli anni '70 e sostituì il 
busulfan per la sua maggior maneggevolezza nel controllo della soppressione 
midollare e per la mancanza di tossicità polmonare. Negli anni '80 fu sperimentato 
nei pazienti affetti da LMC l’uso dell’INF-α. Questo farmaco induce una risposta 
ematologica completa nell’ 50-70% dei pazienti ed una risposta citogenetica (definita 
come percentuale di cellule midollari Ph+ inferiore al 35%) nel 10-20% dei casi. 
Purtroppo la terapia con INF-α induce alcuni effetti collaterali importanti: sintomi simil 
influenzali, calo ponderale e, meno frequentemente, diarrea e neurotossicità che si 
presenta con depressione e deficit anamnestici, cioè disturbi della memoria. L’unico 
intervento curativo è il trapianto allogenico di cellule staminali (AlloSCT); una scelta 
terapeutica  associata ad un elevato rischio di morbidità e mortalità.  
La terapia della LMC è stata profondamente modificata negli ultimi dieci anni dalla 
introduzione di una classe di farmaci noti come “inibitori delle tirosino-chinasi” (TKI). 
Il primo di questi farmaci ad affermarsi nel trattamento della LMC è stato l’Imatinib 
mesilato, cui hanno fatto seguito il Nilotinib e il Dasatinib. I farmaci TKI sono una 
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classe di antineoplastici che appartengono ad una categoria di nuovi farmaci detti “a 
bersaglio molecolare (target) ” o “biologici ” o ancora “intelligenti ”. Caratteristiche 
peculiari e vantaggiose di questi nuovi farmaci sono: 
1. l’azione selettiva su definiti substrati delle cellule tumorali,  
2. la modesta insorgenza di effetti indesiderati, 
3. la possibilità di essere somministrati, in alcuni casi (come nel caso 
dell’Imatinib), per via orale,  
4. la possibilità di utilizzo in associazione con terapie tradizionali.  
L’introduzione di una terapia “a bersaglio molecolare” nella pratica clinica ha 
migliorato drammaticamente la storia naturale della malattia, incrementando la 
sopravvivenza globale dei pazienti con LMC a dieci anni dal 20% all’ 80-90%. 
Nonostante i notevoli progressi ottenuti nella terapia della LMC con i TKI, numerose 
evidenze sperimentali hanno dimostrato chiaramente che inibire l’attività chinasica 
BCR-ABL non è sufficiente ad eliminare la malattia minima residua, la cui 
persistenza è dovuta  ad una  mancata eliminazione delle cellule staminali 
leucemiche nel tessuto midollare. Pertanto una strategia curativa, necessariamente 
deve prevedere la combinazione di un farmaco TKI con agenti che specificamente 
agiscono sulla cellula staminale leucemica all’interno della nicchia midollare. 
Il progetto sviluppato ha inizialmente valutato il ruolo del microambiente tumorale 
nella determinazione degli eventi di leucemogenesi, di progressione e di induzione 
della resistenza al trattamento sia su cellule neoplastiche isolate da pazienti affetti da 
LMC in trattamento con TKI (Farmaci inibitori della tirosin chinasi: Imatinib, Dasatinib 
o Nilotinib) sia su linee cellulari Ph+ immortalizzate.  
A tale scopo le cellule leucemiche derivate dai pazienti in trattamento con i TKI, sono 
state testate per le loro proprietà di adesione e interazione con il mocroambiente 
midollare, con il fine di identificare gli eventuali fattori peculiari che li legano alla 
nicchia osteoblastica midollare. In particolare sono state raccolte le cellule Ph+ 
isolate dai campioni di BM (sangue midollare) e dal PB (sangue periferico) di 
paziente affetti da LMC in pretrattamento e/o durante il trattamento con TKI (in 
particolare al terzo e sesto mese di trattamento).  
In particolare abbiamo ricevuto 41 campioni midollari e 41 campioni periferici in pre-
trattamento (Visita 1) e 40 campioni (sia midollari che periferici per ogni singolo 
paziente) alla Visita 2 (alla fine del terzo mese) e alla Visita 3 (fine del sesto mese). 
Dai 41campioni midollari e/o periferici in pre-trattamento abbiamo selezionato la 
popolazione cellulare CD34+ e 14 popolazioni di cellule stromali MSCA+ . Dai 40 
campioni biologici arrivati alla visita successiva non abbiamo ricavato un numero 
sufficiente di cellule da poter selezionare le cellule CD34+ o MSCA+. 
L’antigene CD34 si ritrova sulle cellule progenitrici ematopoietiche di tutte le linee 
così come la maggior parte delle cellule staminali primitive totipotenti. L’antigene 
CD34 ha la sua massima espressione sulla maggior parte delle cellule staminali 
primitive e viene gradualmente perso quando le cellule progenitrici predestinate della 
linea si differenziano. L’antigene CD34 é anche presente sulle cellule endoteliali 
capillari e sulle cellule stromali del midollo osseo. L’antigene CD34 é espresso in 
circa il 60% dei casi di leucemia acuta, sia linfoide che mieloide.  
Nelle CML, l’aumento del numero di CD34+ può essere un indice rilevante della 
progressione a fase accelerata o blastica. 
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Le cellule CD34+ sono state selezionate dalle cellule mononucleate totali dopo 
separazione immunomagnetica usando il kit MiniMACS per le cellule CD34 (Miltenyi 
Biotec), secondo le istruzioni della ditta produttrice.  
Le cellule staminali si distinguono in totipotenti, capaci di trasformarsi in qualsiasi tipo 
di tessuto; pluripotenti, che si trasformano solo in alcuni tipi di tessuti;  unipotenti, che 
possono dar luogo soltanto ad un tipo cellulare.  Le cellule staminali mesenchimali 
sono una popolazione cellulare pluripotente. 
Le “cellule staminali mesenchimali” (MSCs), dotate di capacità di automantenimento 
e differenziativa in senso osteoblastico, condrocitario, adipocitario, mioblastico e 
fibroblastico. Sono anche denominate “cellule stromali midollari”, data la loro 
capacità di generare le cellule del microambiente midollare. Infatti, le cellule staminali 
mesenchimali sono contenute all'interno dello stroma midollare.  
L’ anti-MSCA (W8B2) è un anticorpo sviluppato per l’isolamento delle cellule stromali 
mesenchimali (MSC) dall’aspirato midollare. L’espressione dell’antigene MSCA-1  è 
ristretto, nella popolazione cellulare midollare, alla frazione CD271bright. Le cellule 
MSC CD271brightCD45dim hanno un’altissima capacità clonogenica comparata alla 
frazione midollare CD271+CD45+.  
Le cellule MSCA+ sono state selezionate dalle cellule mononucleate totali dopo 
separazione immunomagnetica, secondo le istruzioni della ditta produttrice. 
Nella prima parte del lavoro scientifico abbiamo osservato sperimentalmente che sia 
le linee Ph+ (K562, KT1 o BV173) che cellule staminali CD34+Ph+ sono 
significativamente protette dalla mortalità cellulare TKI-dipendente (Imatinib, Nilotinib 
o Dasatinib) quando incubate in presenza (direttamente o separate da una 
membrana che lascia passare solo i fattori solubili) della linea cellulare stromale HS5 
o di linee stromali MSCA+ ottenute ex-vivo da campioni midollari isolati da pazienti 
affetti da LMC alla diagnosi. 
Inoltre, ho osservato nel mio studio sperimentale che la resistenza è BCR-ABL 
indipendente, mediata presumibilmente dalla attivazione della cascata JAK-STAT3. 
Infatti, il co-trattamento delle linee tumorali Ph+ con uno dei TKI e un inibitore 
specifico della tirosin chinasi non recettoriale JAK2 è in grado di superare questa 
resistenza. Inoltre le due categorie di farmaci hanno mostrato un significativo effetto 
sinergico nell’azione terapeutica. 
Nella parte finale del progetto, con il fine di determinare il ruolo esatto dei differenti 
fattori di crescita e delle citochine nella sopravvivenza delle cellule leucemiche, 
abbiamo determinato mediante il saggio ELISA assay BioPlex il livello di espressione 
contemporaneamente di 20 differenti citochine prodotte dalle cellule stromali isolate 
da pazienti affetti da LMC alla diagnosi o dalla linea immortalizzata HS5. I fattori 
solubili valutati sono stati: IL1a, IL1b, IL3, IL6, IL7, IL8, IL10, IL12, IL15, G-CSF, M-
CSF, SCF, SDF1, TRAIL, HGF, PDGFbb, GM-CSF, MIP-1a, TNFa e VEGF. Questi 
fattori sono noti avere un ruolo chiave nell’interazione delle cellule staminali Ph+ con 
il microambiente midollare. 
Quindi, tutte le citochine espresse sia dalle cellule HS5 che dalle cellule stromali 
ottenute dai pazienti affetti da LMC, sono state poi testate in vitro per verificare se e 
come andassero a modulare la risposta farmacologica delle cellule Ph+ ai TKI. Il 
saggio ELISA assay BioPlex è stato effettuato sul mezzo di 24 ore di coltura della 
linea stromale HS5 (HS5/SCM) e sui mezzi condizionati derivanti dalla coltura delle 
cellule stromali ottenute da 8 differenti pazienti affetti da CML (CML/SCM). Nel nostro 
saggio abbiamo identificato una serie di fattori altamente espressi in entrambe le 
linee cellulari, quali il fattore G-CSF, IL-6, IL-8 e VEGF, conosciuti avere un ruolo 
fondamentale nell’attivazione di STAT3 e quindi della via JAK/STAT3. 
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Recentemente utilizzando topi knock-out per STAT3 si è dimostrato il suo ruolo 
fondamentale nel dare origine alla malattia, ma non nel mantenimento della stessa. 
Nel contesto del microambiente midollare, STAT3 è attivato in maniera BCR-ABL 
indipendente dalle citochine presenti nel mezzo di coltura dello stroma midollare. 
Quindi l’attivazione della via JAK/STAT3 contribuisce alla sopravvivenza del clone 
staminale leucemico anche in presenza dei TKI. I nostri dati suggeriscono che la via 
JAK/STAT3 è un bersaglio terapeutico interessante nell’ottica di una terapia 
combinatoria con i TKI, e rappresenta una strategia vitale nell’eliminare o almeno 
ridurre la malattia minima residua dei pazienti affetti da LMC.  
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SUMMARY 
 
The importance of tumor microenvironment for cancer progression is becoming 
widely recognized in recent years. The Bone Marrow (BM) is a dynamic 
microenvironment with high concentration of growth factors and cytokines necessary 
for haematopoiesis, making it a highly permissive zone for cancer haematopoietic 
staminal cell homing and survival. It is possible that the same factors that modulate 
hematopoiesis promote leukemogenesis, enhance blast survival and make them 
resistant to treatment within the BM microenvironment. In the era of molecular target 
therapy, whereas Imatinib has shown a cumulative best complete cytogenetic 
response rate of 82% and an estimated event free survival at 8 years of 85%, several 
in vitro data have confirmed that Ph+ CD34+ progenitor cells crammed in BM niches 
are resistant to TKI treatments. We attempted to define BM microenvironment 
markers that nurture and determine stem cell fate in leukemia associated-niches.  
We treated Ph+ K562 cell lines and primary CD34+ BM cells derived from untreated 
CML patients with a dose range of TKIs (0-100µM) in the presence of a monolayer of 
human BM mesenchimal stromal cell line (HS-5) or HS5 conditioned media (HCM), to 
assess the role of BM niche in the regulation of TKI responsiveness. We 
demonstrated that BM stroma environment significantly protects K562 cell line from 
TKI-induced apoptosis. Indeed, we demonstrated that Half maximal inhibitory 
concentration (IC50) value (calculated on cell viability) of Imatinib, Nilotinib and 
Dasatinib significantly increased when leukemic cells are exposed to HS5 or HCM. 
Moreover, we prove that a significant TKI-resistance could be achieved also by Ph+ 
CD34+ primary CML cells exposed to HS5 or HCM.  
Taken together, these findings indicate that BM-derived stroma cell line produces a 
strong effect on the regulation of TKI responsiveness in Ph+ CML cells by both a 
direct cell-to-cell contact and exposition to soluble factors. Moreover, the observed 
TKI resistance is associated to a BCR-ABL independent STAT-3 activation leading to 
a significant down-modulation of apoptosis when either Ph+ cell line or primary 
CD34+ progenitor cells derived from patients with CML are treated with TKIs in the 
presence of a direct mesenchymal stroma cell interaction or exposition to SCM. 
Finally, I proved that JAK inhibitor Ruxolitinib, that inhibits STAT3 phosphorylation (a 
marker of JAK activity), synergizes with TKIs in the induction of apoptosis in CML 
primary cells. Indeed, compared with single agent treatment, exposure of CML cells 
to the combination of TKI and JAK inhibitor Ruxolitinib significantly decreased 
viability of CML cells and increased their apoptosis in vitro. Taken together, our data 
show that the rational drug combination of TKI and Ruxolitinib may enhance the 
eradication of primary human Ph+ cells homed in BM stroma niche. 
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BONE MARROW MICROENVIRONMENT 
 
The bone marrow provides a framework of microenvironmental domains or niches 
that support the function of immune cells and Haematopoietic Stem Cells (HSCs). 
Cellular niches are functional compartments within tissues that control cell numbers 
by providing signals that regulate self-renewal, differentiation and quiescence. Such 
signals can be transmitted both via direct cell-to-cell contact, or by growth factors 
cytokines and components of the extracellular matrix. The concept of the HSC niche 
was first proposed by Schofield in 1978 to describe the physiologically limited 
microenvironment in which stem cells reside. The niche hypothesis has been 
supported by a variety of coculture experiments in vitro [1–2]. Normal hematopoiesis 
occurs in a unique Bone Marrow (BM) microenvironment that is of fundamental to the 
production and differentiation of normal hematopoietic progenitor cells. Such 
hematopoietic cell development is regulated by BM stromal cells (BMSC) through the 
production of cytokines and intracellular signals initiated by cellular adhesion [3].  
BM resides within the protected confines of the bones. In adults, 4.6% of body weight 
is due to the BM that is distributed throughout the vertebrae, ribs, pelvis, skull and 
proximal ends of the long bones. The fundamental objective of the BM is to maintain 
the numbers of differentiated hematopoietic cells in the peripheral blood at a constant 
level throughout the life time of a human being. The BM does this by producing an 
estimated 500 billion cells per day [4]. The structure of the BM consists of a rigid 
bone cortex enclosing a cavity containing the arterial vascular system, a complex 
sinusoidal system, hematopoietic cells and the stroma. Arterial vessels enter the BM 
and divide into arterioles and capillaries that span throughout the BM [5]. The cellular 
component of the BM can be divided into Hematopoietic Cells and Mesenchymal-
Derived Cells.  
The mesenchymal-derived cells, along with the macrophages and the extracellular 
matrix (ECM), form the BM stroma.  
The main constituents of the BM extracellular matrix (ECM) include fibronectin (FN), 
hyaluronan, collagen types I and IV, laminin, glycosaminoglycans heparin sulfate and 
chondroitin sulfate. In addition to providing the structural scaffold for cellular elements 
of the BM, ECM also exerts its effect on cell growth, differentiation, motility and 
viability. The ECM molecules function as a reservoir of many secreted growth factors, 
cytokines, matrix metalloproteinases and other processing enzymes whose 
availability is regulated by arrangement of the matrix, thus creating stromal niches 
within the BM [6]. 
Osteoblasts play a central role in skeletal development. Derived from pluripotent 
BMSC, they mature along a specific lineage to become highly specialized cells. 
Primary human osteoblasts produce growth factors, including granulocyte colony 
stimulating factor G-CSF, that are likely essential for the survival of CD34+ BM cells 
and support the growth of CD34+ human BM progenitor cells in vitro [7]. Some recent 
studies have suggested that osteoblasts are critical regulators of hematopoietic stem 
cells (HSCs) microenvironment [8-9].  
Adipocytes, which are the prevalent type of stromal cells in adult BM, also play an 
important role in the hematopoietic environment. In particular, the adipocyte 
differentiation of BMSC has been shown to positively correlate with the ability of the 
BM microenvironment to support the growth of lymphoid cells. [10]. They produce the 
leptin and multiple cytokines, including stromal-derived factor-1 (SDF-1), M-CSF, 
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GM-CSF, SCF, thrombopoietin, IL-6, LIF, and transforming growth factor β (TFG-β) 
[11]. Preadipocytes also strongly express fibronectin, an adhesive ECM protein that 
promotes leukemia development [12]. These mechanisms may be important to the 
interactions between leukemic and stromal cells that occur in vivo, with a potential of 
promoting chemoresistance in leukemias [13]. The hematopoietic stem cells (HSCs) 
and hematopoietic progenitor cells (HPCs) are held within the BM stroma not only 
through the adhesive interactions between VCAM-1, expressed by stromal cells, and 
integrin α41 (alpha 4 beta 1) expressed by the HSCs and HPCs, but also by the 
chemotactic interaction between the chemokine CXCL12 and its receptor CXCR4 
expressed on the HSCs and HPCs. In steady-state conditions the majority of the 
HSCs reside in the BM with a few circulating in the peripheral blood. HSCs are 
localized in a non random manner at the bone–BM interface (osteoblastic niche) and 
around the blood vessels (vascular niche).  
  
The Osteoblastic Niche 
The majority of HSCs in the endosteum are found to be in direct contact with the 
osteoblasts. The HSCs home in on the endosteum with the help of a chemotactic 
Ca2+ sensing receptor that senses the Ca2+ gradient within the BM. The gradient is 
created by the release of Ca2+ in the BM due to the constitutive osteoclasts and 
osteoblasts-mediated bone remodeling.[54] Once reaching the endosteum, the HSCs 
are held in the endosteum by the expression of: 
 Adhesive molecules like osteopontin, 
 N-cadherin,  
 Transmembrane c-KIT ligand stem cell factor (SCF)  
 The polysaccharide hyaluronic acid. 
 
This interaction is strengthened by the cytokines and chemokines that are produced 
by the osteoblasts, like:  
 Chemokine CXCL12, also known as SDF-1 
 Angiopoietin-1 (Ang1),  
 Jagged-1, a ligand for Notch1 receptor also expressed by HSCs. 
 
Osteopontin, a matrix glycoprotein expressed by the osteoblasts supports the 
adhesion of HSC to the osteoblastic niche and negatively regulates HSC 
proliferation, contributing to the maintenance of a quiescent state.  N-cadherin, is 
expressed in HSCs or HPCs and they plays a critical role in the regulation of 
HSCs/HPCs engraftment. Osteoblasts in the bone marrow produce a significant 
amount of membrane-bound stem cell factor (SCF), which has the capacity to 
enhance the adhesion of HSCs to stromal cells. [56] SCF binds and activate c-KIT (a 
receptor tyrosine kinase), which is highly expressed by HSCs. Hyaluronan is 
synthesized by primitive HSCs, participates in their lodgment at the endosteum. 
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Secreted Factors 
The bone-forming osteoblasts are crucial players for the homeostasis of the 
hematopoietic tissue with its high turn-over. Indeed, osteoblasts express several cell-
signaling molecules such as BMP4, Jagged-1, and angiopoietin-1 (Ang1), both are 
important for HSCs self-renewal, survival, and maintenance.  CXCL12 a member of 
the CXC subfamily of cytokines, also known as Stromal derived factor-1 (SDF-1) is 
produced by stromal cells and, acting through the G protein–coupled CXCR4, the 
sole receptor for SDF-1. SDF-1 functions as both a chemo-attractant and a 
modulator of cellular growth/ survival. Ang1 in osteoblasts interacts with the tyrosine 
kinase receptor Tie-2, a type of receptor tyrosine kinase that is expressed in HSCs, 
and the Tie-2/Ang1 interaction activates 1-integrin and N-cadherin. This enhanced 
adhesion contributes to the maintenance of the stem cell quiescence.  Osteoblasts 
expressing the Notch ligand: Jagged1. Jagged1-mediated Notch1 signaling is 
dispensable for HSCs self-renewal and differentiation. 
 
The Vascular Niche 
The vascular niche promotes proliferation, differentiation of actively cycling, and 
short-term HSCs.  The most purified HSCs, fractioned as CD150+ CD48− CD41− 
Lin−cells, were found in majority to be associated with the sinusoidal endothelium 
lining blood vessels, suggesting that endothelial cells create a cellular niche for 
HSCs.  
 
Secreted Factors 
The vascular niche has been shown to produce factors important for mobilization, 
homing, and engraftment of HSCs, such as CXCL12 (SDF-1, stromal cell derived 
factor-1) important for mobilization, homing, and engraftment for HSCs.  SDF-1 and 
FGF-4 (fibroblast growth factor-4) induce upregulation of adhesion molecules, 
including VLA4/VCAM1, facilitating localization to the vascular niche.  
CXCL12/CXCR4 signaling plays important roles in HSCs trafficking and HSCs 
mobilization. HSCs were specifically located adjacent to cells expressing a high level 
of CXCL12, which surrounded the sinusoidal endothelial cells. They named these 
cells CXCL12-abundant reticular cells (CAR). HSCs have been shown to be 
associated with CAR cells in the sinusoidal region and are located between CAR and 
osteoblastic cells in the endosteal region, suggesting that those cells might be an 
important component of both the osteoblastic and the vascular niches in adult BM. 
 
Membrane-Bound Factors 
During the bone marrow transplantation, the ability of HSCs to “home” and engraft in 
the recipient’s bone marrow requires a cascade of events which includes specific 
molecular recognition. Adhesion molecules on the HSCs involved in the process of 
rolling are VLA4 (CD49d), LFA-1 (CD11a), and hyaluronan binding cellular adhesion 
molecule (HCAM/CD44) whereas the complementary binding partners on the BM 
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endothelial cells are VCAM-1, ICAM-1 (CD54), and E- and P-selectin (CD62E and 
CD62P).[62]  
 
Difference between vascular and osteoblastic niches. 
The major difference between both microenvironments is the oxygen level. Higher in 
the vascular niche than in the osteoblastic niche under hypoxia, HSCs would move to 
the vascular niche and resume then cell cycle in order to restore hematopoiesis. The 
osteoblastic niche localized at the inner surface of the bone cavity and with abundant 
osteoblasts, might serve as a reservoir for long-term HSC storage in a quiescent 
state. Whereas the vascular niche, which consists of sinusoidal endothelial cell lining 
blood vessel, provides an environment for short-term HSC proliferation and 
differentiation. Both niches act together to maintain hematopoietic homeostasis or 
restore it after damage.  
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Figure 1. Schematic representation of the molecular interactions between 
hematopoietic stem cells and their niches in the bone marrow. In normal 
physiological conditions, the hematopoietic stem cells (HSCs) reside either at the 
endosteum, lodged with the osteoblasts (OBT) (osteoblastic niche) or at the 
sinusoidal vessels (SV) (vascular niche). The osteoblastic niche provides the 
microenvironment for HSC maintenance and quiescence and the vascular niche 
provides the microenvironment for HSC proliferation and differentiation. The oxygen 
and the calcium gradient might play a crucial role in maintenance of the different 
niches within the bone marrow.   
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Mesenchymal Stem Cells 
The key component of the BM is Mesenchymal Stromal Cells (MSC). These plastic-
adherent cells currently described as mesenchymal stem cells are termed multipotent 
mesenchymal stromal cells, while the term MSCs should be reserved for a subset of 
these cells that demonstrate stem cell activity by clearly stated criteria [14]. MSCs 
are primitive cells originating from the mesodermal germ layer and were classically 
described to give rise to connective tissues, skeletal muscle cells, and cells of the 
vascular system. Friedenstein and colleagues (1974) first described MSC as 
fibroblast-like cells that could be isolated from BM via inherent adherence to plastic in 
culture. BM-derived MSC are primitive, undifferentiated cells that are capable of self-
renewal and of giving rise to different cell lineages, including adipocytes, osteocytes, 
fibroblasts, chondrocytes, and myoblasts. Thus, MSCs are key components of the 
hematopoietic microenvironment. One of the main functions of MSCs is to provide, 
within the BM, a microenvironment that is conducive for hematopoiesis. It does so by 
not only differentiating into the various cellular components of the BM stroma, but 
also by providing a scaffold for cell to cell interactions and by secreting cytokines and 
growth factors. MSCs rely on the transforming growth factor-β (TGF-β) family of 
proteins in governing its development and differentiation. Even if TGF-β itself 
promotes the expansion of undifferentiated MSCs, other TGF-β family members in 
cooperation with specific transcriptional regulators promote the differentiation of 
MSCs. For example, transcription factor Runx2 drives MSCs to differentiate into 
osteoblasts and the transcription factor peroxisome proliferator-activated receptor 
(PPARγ) drives the differentiation of MSCs into adipocytes [15-16]. In addition, it has 
also been demonstrated that MSCs are capable of differentiating into 
cardiomyocytes, neurons, and astrocytes in vitro and in vivo [17]. MSC constitutively 
express the mRNA for interleukin (IL)-6, IL-11, leukemia inhibitory factor (LIF), 
macrophage colony-stimulating factor (M-CSF), and stem cell factor (SCF) and can 
express granulocyte colonystimulating factor (G-CSF) and granulocyte macrophage 
colony-stimulating factor (GM-CSF) upon IL-1α stimulation [18]. MSCs are also 
considered the major source for the secretion of the homeostatic chemokine, 
CXCL12 which has a role in both homing and circulation of hematopoietic cells [19]. 
MSCs play a fundamental role in lymphopoiesis by aiding the development of the 
naïve B cells in the BM and  the development of T cells via the process of extra-
thymic T cell lynphopoiesis [20]. MSCs through the production of CXCL12, assist in 
the homing of CD8+ T cells into the BM and thus mediate the induction of adaptive 
immunity in response to antigen HSCs and in immune responses. This ability of MSC 
to produce cytokines coupled with the multiple mechanisms in the ECM that directly 
support MSC and their pleiotropic capacity are also conducive to the development of 
leukemic cells. Phenotypically MSCs express a number of markers, none of which 
are specific only to MSCs. It is generally agreed that adult human MSCs do not 
express the hematopoietic markers CD45, CD34, CD14, or CD11. They also do not 
express the costimulatory molecules CD80, CD86, or CD40 or the adhesion 
molecules CD31, CD18, or CD56, but they can express CD105 (SH2), CD73 
(SH3/4), CD44, CD90 (Thy-1), CD71, and Stro-1 as well as the adhesion molecules 
CD106, CD166, intercellular adhesion molecule, and CD29 [21-22]. Although there 
are no unique cell surface markers for the identification of MSCs, minimal criteria to 
define human MSC have been published. According to such criteria, MSC must be:1) 
plastic-adherent; 2) express CD105, CD90 and CD73; 3) lacking expression of 
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CD45, CD34 and CD14; 4) show in vitro differentiation capabilities into osteoblasts, 
adipocytes and chondroblasts [22-23]. 
 
 Endothelial Cells and Angiogenesis 
The microvasculature is an active component of the stroma and is responsible for 
supplying the appropriate oxygen and nutrients. It provides a route for homing and 
metastasis as well, and the BM endothelial cells are also involved in autocrine and 
paracrine interactions with leukemic cells [13]. The synthesis of Vascular endothelial 
growth factor (VEGF) and other angiogenic factors such as basic fibroblast growth 
factors (bFGF) and hepatocyte growth factor (HGF) has been observed in leukemic 
cells. Interestingly, VEGF signaling in HSCs is involved in regulating cell survival by 
means of an internal autocrine loop mechanism that involves both VEGF receptors 
(VEGFR-1 and -2) [25]. VEGF is an essential regulator of physiologic and pathologic 
angiogenesis. For example, VEGF secreted by leukemic cells activates receptors on 
both leukemic and endothelial cells. In chronic myeloid leukemia (CML), VEGF is 
expressed at high levels in the BM and peripheral blood; moreover, the CML-
associated oncogene BCR-ABL induces VEGF- and hypoxia inducible factor-1α 
(HIF1α)-gene expression via phosphoinositide 3-kinase (PI3K)-mTOR– dependent 
pathway [26]. It is therefore conceivable that the expression of HIF target genes, 
such as VEGF, plays an important role in leukemia progression, therapy response, 
and outcome [27]. On the basis of in vivo and ex vivo studies, BM endothelial cells 
were found to express factors that promote haematopoiesis, such as granulocyte 
colony stimulating factor (G-CSF), granulocyte–macrophage colony-stimulating factor 
(GM-CSF), macrophage colony-stimulating factor (M-CSF), stem cell factor (SCF; 
also known as KIT ligand), interleukin‑6 (IL‑6) and FMS-related tyrosine kinase 3 
ligand (FLT3L; also known as FLK2 ligand). In addition, these cells were shown to 
express the adhesion molecules E-selectin, P-selectin, vascular cell adhesion 
molecule 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1)[28].  
The BM vasculature is heterogeneous in its expression of molecules that are thought 
to facilitate cell homing, such as E‑selectin and CXCL12. Such homing pathways can 
also be exploited by malignancies that can metastasize to the BM [29-30-31]. In vitro, 
immortalized endothelial cells can support HSC function in culture through the 
expression of Notch ligands [32]. Similarly, the expression of a constitutively active 
mutant form of AKT in endothelial cells (using a cell-specific inducible transgenic 
mouse model) leads to an increase in HSC numbers [33]. These characteristics 
support the idea that endothelial cells can provide niche functions in vivo, although 
conclusive evidence that they do so is not yet in hand. Endothelial cells are 
surrounded by perivascular MSCs, which provide structural support and harbor 
populations of cells that can regenerate the BM stroma and interact directly with 
HSCs. Under steady-state conditions, most stem cells are in contact with BM stromal 
cells, including osteoblasts, and are maintained in G0 phase of cell cycle [34]. 
Although a small fraction is in S or G2/M phase of the cell cycle. The equilibrium 
between these two compartments is dictated by the bioavailability of stem cell-active 
cytokines, which are bound to the extracellular matrix or tethered to the membrane of 
stromal cells. Stress, such as BM ablation by cytotoxic agents, switches on 
sequences of events where HSCs are recruited from their niches to reconstitute 
hematopoiesis. Local secretion of proteases may alter the stem cell-stromal cell 
interaction. The proteolytic cleavage of vascular cell adhesion molecule-1, expressed 
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by BM stromal cells, is triggered by the degranulation of neutrophils in the BM after 
G-CSF administration and may be an essential step contributing to the mobilization 
of hematopoietic progenitors. Matrix metalloproteinases (MMPs) promote the release 
of extracellular matrix-bound or cell-surface-bound cytokines such as VEGF, which 
then can regulate angiogenesis or osteoclast recruitment [36-37-38].
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Figure 2. In the bone marrow, haematopoietic stem cells (HSCs) can be found near 
the endosteal surface (a); in association with CXCL12-abundant reticular (CAR) cells 
(b); and in the periphery of sinusoids and perivascular nestin-expressing cells (c). 
Each niche is thought to provide signals that support HSC behavior, although the 
relationship between HSCs that are present in different niches is still unclear (dotted 
arrows). Likewise, blood vessels in the bone marrow are often in close association 
with bone, although their interaction is still poorly understood (d). At the endosteal 
surface, osteoblastic cells express factors that participate in HSC retention; 
osteoclasts regulate osteoblastic cell function by inducing bone remodelling. In the 
bone marrow stroma, HSCs are associated with CAR cells, which express factors 
that promote HSC retention. Adipocytes negatively regulate HSCs in the steady 
state. In the perivascular area, HSCs are associated with nestin-expressing cells, 
which promote HSC retention and are regulated by macrophages and the 
sympathetic nervous system (SNS). 
  
 
19 
 
Hematopoiesis and vascularization occur concurrently during development. In fact, 
HSCs and endothelial cells are derived from the same progenitor cells 
(hemangioblasts) at the embryonic stage and are closely related to the ontogeny of 
hematopoiesis that occurs in the yolk sac, aorta-gonad-mesonephros, placenta, fetal 
liver, spleen, and adult BM. The BM vascular structure provides a barrier between 
the hematopoietic compartment and the peripheral circulation. Most primitive HSCs 
remain physiologically quiescent within the BM niche; however, a portion of HSCs 
leave this resting pool and initiate the process of mobilization [37-38-39]. There are 
some controversial reports suggesting that mobilized HSCs may be more quiescent 
than those that remain in the BM. Evidence to support this notion comes mainly from 
a study in which the CD34+ marker was used to identify HSCs and HPCs [42]. Since 
the population of CD34+ cells included numerous progenitor cells BM endothelial 
cells have been proposed to play a role in HSC controlling within vascular niche. 
Primary CD34+ microvascular endothelial cells can restore hematopoiesis in mice 
when they receive lethal doses of irradiation [43]. Selective activation of AKT in 
endothelial cells produced angiocrine factors mediated in the reconstitution, 
expansion, and maintenance of HSCs [44]. Nonetheless, constitutively activation of 
AKT, a binding ligand of phosphoinositide 3 in the phosphoinositide 3-kinase 
pathway, impaired engraftment ability and generated leukemia in mice [45]. Reticular 
cells located around the sinusoid endothelium could produce stromal cell-derived 
factor 1 (SDF-1, also CXCL12) mediated in HSC niche. These cells have been 
named CXCL12 abundant reticular cells (CAR cells). The shuttle of HSCs between 
vascular and endosteal niches is a important phenomena involving CXCL12/CXCR4 
signaling. This signaling is essential in maintaining the HSC pool, development of B 
cells and plasmacytoid dendritic cells [46-47]. 
 
Hierarchy of Human Hematopoiesis 
The origin of all blood cells in hematopoietic system is believed to be derived from 
HSCs that contain self-renewal capacity and give rise to multipotent progenitors 
(MPPs) which lose self-renewal potential but remain fully able to differentiate into all 
multilineage cells. MPPs further give rise to oligopotent progenitors which are 
common lymphoid and myeloid progenitors (CLPs and CMPs, resp.).  
All these oligopotent progenitors differentiate into their restricted lineage 
commitment: (1) CMPs advance to megakaryocyte/erythrocyte progenitors (MEPs), 
granulocyte/macrophage progenitors (GMPs), and dendritic cell (DC) progenitors, (2) 
CLPs give rise to T cell progenitors, B cell progenitors, NK cell progenitors and DC 
progenitors. Notably, DC progenitors (CD8α+ DC, CD8α− DC, and plasmacytoid DC) 
could be derived from both CMPs and CLPs [48-49]. Among the isolation and 
characterization of HSCs and progenitors, CD34 molecule is the ﬁrst widely chosen 
for the study by several researchers. CD34 is comprised in the CD34 family of cell-
surface transmembrane proteins together with podocalyxin and endoglycan [50-51]. 
CD34 expression on blood cells is about 0.1–4.9% in human cord blood, bone 
marrow, and peripheral blood [52-53] . 
The balance that controls between self-renewal and differentiation (or cell fate 
decision) of HSCs in the bone marrow is mediated by several factors. Most HSCs are 
in quiescent state (i.e., in G0/G1 phase of the cell cycle). However, when the 
hematopoietic cell disturbance occurs, hematopoiesis system will respond by [54]. 
shutting down or turning on specific signals. Several pathways have been employed 
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in this regulation, including SDF-1 (CXCL12)/CXCR4, BMP, Mpl/Thrombopoietin 
(TPO), Tie2/Ang-1, Hedgehog and Notch, as well as Wingless (Wnt). SDF-1 belongs 
to α-chemokines that functions as chemoattractant for both committed and primitive 
hematopoietic progenitors and regulates embryonic development including organ 
homeostasis [55].  
Bone morphogenic proteins (BMPs) are a group of growth factors that belongs to a 
TGF-β family member [56]. BMPs are mainly produced by osteoclasts in HSC niche 
[57]. BMP signaling impairment displayed an increase in the niche size, leading to 
the enhancement in the number of HSCs [58]. c-Mpl and its ligand, thrombopoietin 
(TPO), are known to regulate megakaryopoiesis [59]. c-Mpl receptor is expressed 
mainly on HSCs, with a lesser extent on megakaryocytic progenitors, 
megakaryocytes and platelets [4]. Angiopoietin-1 (Ang-1) is the ligand of Tie2, a 
receptor tyrosine kinase, which expresses predominantly on osteoblastic cells in 
endosteum [60] and in MSCs [61]. Interaction of Tie2 with its ligand, Ang- 1, resulted 
in tightly adhesion of HSCs to the niche and become more quiescence. Hedgehog 
(Hh) is proposed as a negative regulator of the HSC quiescence [62]. Hh ligand 
binds to the transmembrane receptor Patched (Ptc) and subsequently allows the 
signaling function of a second transmembrane protein, Smoothened (Smo), 
essentially for the Hh signal to be active, but in contrast it has been demonstrated 
that constitutive activation of the Hh signaling pathway in Ptc heterozygous (Ptc-1 
+/−) mice resulted in induction of cell cycling and expansion of primitive BM 
hematopoietic cells [63]. Notch signaling plays a key role in several fundamental 
functions including proliferation, differentiation and cell fate decision [63-64]. Four 
notch receptors (Notch 1–4) and ﬁve ligands (Jagged1-2 and Delta-like 1, 3, and 4) 
have been identiﬁed in mammals [65]. Several studies support the role of Notch 
signaling mediating the regulation of HSC hematopoiesis and self-renewal 
maintenance [66]. 
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CHRONIC MYELOGENOUS LEUKEMIA 
 
Chronic myelogenous leukaemia (CML) results from the neoplastic transformation of 
a haematopoietic stem cell. CML leukemia stem cells (LSCs) retain the ability to 
regenerate multilineage hematopoiesis and generate a vast expansion of malignant 
myeloid cells, which retain differentiating capacity and displace residual normal 
hematopoiesis. CML cells also demonstrate altered trafficking resulting in increased 
numbers of circulating progenitors, extramedullary hematopoiesis, and massive 
splenomegaly.LSCs acquire additional genetic abnormalities over time, leading to 
disease progression from an initial chronic phase (CP) to advanced accelerated 
phase (AP) and blast crisis. 
In CML, the course is marked by three distinct phases: 1) chronic phase with stable 
clinical situation and the absence or rarity of symptoms; 2) accelerated phase, which 
typically occurs after 3-5 years and in which there is a worsening of all the clinical 
and haematological and finally, 3) blast phase in which there is essentially a 
transformation in acute leukemia. The first step, as mentioned, is very variable, 
whose median duration is three years, which means that half of the patients 
undergoes blast crisis within the first three years after diagnosis. In the accelerated 
phase, which usually lasts few months, there is a loss of response to standard 
treatments. In the blast phase, both in the absence of therapy or in patients 
undergoing aggressive treatments, the survival is ranging from few months to few 
weeks, as it is difficult to induce a second chronic phase stability. 
 The hallmark genetic abnormally of CML is a t(9;22) (q34;q11) translocation, which 
was first discovered as an abnormal, small chromosome, named the ‘Philadelphia 
chromosome’ (Ph). At molecular level, the Ph translocation results in the juxtaposing 
of the 5' part of the BCR gene to the 3' part of the ABL gene, and, depending on 
chromosomal breakpoint locations, different parts of these two genes may be 
included in the oncogenic fusion gene. The ABL gene is a gene encoding a non 
receptor tyrosine kinase that is expressed in most tissue. It is generally accepted that 
acquisition of the BCR-ABL1 oncogene is the initiating event in the genesis of CML-
CP, despite various lines of evidence suggesting that, at least in some cases, 
hematopoiesis may already be clonal before the acquisition of the Ph chromosome. It 
is believed that acquisition of the BCR-ABL1 gene occurs initially in a single HSC that 
gains a proliferative advantage and/or aberrant differentiation capacity over its 
normal counterparts, giving rise to the expanded myeloid compartment. In cells, the 
ABL protein is distributed in both the nucleus and cytoplasm of cells and shuttles 
between the two compartments. It transduces signals from cell-surface growth factor 
and adhesion receptors to regulate cytoskeleton structure. BCR is also signaling 
protein that contains multiple modular domains. The fusion of BCR sequences to 
ABL during the translocation associated with CML increases the tyrosine-kinase 
activity of ABL, and brings new regulatory domains/motifs to ABL, such as the growth 
factor receptor-bound protein 2 (GRB2) SH-2 biding site. ABL spans a 230 kb region 
at band q34 of chromosome 9 and consists of 11 exons, with two first alternative 
exons, i.e. exons Ia and Ib. In the vast majority of the Ph positive patients, 
breakpoints in the ABL gene appeared to be distributed over a rather large 300 kb 
fragment of chromosome 9 at band q34. BCR-ABL activates a number of 
downstream targets including RAS, PI3 kinase, NF-κB and signal transducer and 
activator of transcription 5 (STAT5), resulting in cytokine-independent growth, 
resistance to apoptosis, and altered cellular adhesion. Classical CML usually shows, 
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at least in the initial chronic phase, a prominent, but often asymptomatic increase in 
peripheral blood of WBC, and in some cases of platelet count associated with the 
presence of immature granulocytic elements. This leukemia is almost invariably 
derived by the P210-encoding BCR/ ABL gene, and it is the prototype of a stem cell 
neoplasia, in which all the hemopoietic lineages derive from a staminal transformed 
cell and have the Ph chromosome. In the classical CML, however, only the myeloid 
and megakaryotytic compartments show a neoplastic expansion, and the 
granulocytic progenitors have a moderate degree of impairment of their differentiation 
and maturation capacity, whereas the erythroid, monocytic and B-and T-lymphoid 
lineages do not reveal any functional damage.  
Expression of BCR-ABL in human CD34+ cells causes increased proliferation in 
response to growth factors, increased growth factor-independent survival, reduced 
adhesion to fibronectin and reduced chemotaxis to stroma-derived factor-1α. These 
properties of BCR-ABL-expressing human haematopoietic progenitor cells mimic 
those of CML progenitor cells isolated from patients. BCR-ABL activates diverse 
progrowth and prosurvival mechanisms, which confer resistance to apoptosis. These 
include increased phosphorylation and transactivation by STAT-5 (signal transducer 
and activator of transcription), which leads to increased expression of the 
antiapoptotic Bcl-xL and Pim-2 protein, and increased Ras/Raf/MEK/ERK1/2, AKT, 
and NFkB activity. BCR-ABL TK activity also leads to depletion of the cyclin-
dependent kinase-2 inhibitor p27 and the BH3 domain-only–containing proapoptotic 
Bim protein.  
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Figure 3: The Ph chromosome is result from translocation the 3 'end of the ABL gene 
on chromosome 9 with the 5' end of the BCR gene on chromosome 22. The 
breakpoints in ABL1 gene are distributed in an area of size greater than 300 Kb and 
are localized at the 5 'exon 2 in most cases. The BCR gene identified a number of 
break-point; different fragments of BCR will be merged with the sequences 3 'ABL1. 
This results in mRNA (e1a2, b2a2, b3a2 and e19a2) of different lengths, translated 
into different protein products (p190, p210 and p230). 
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CML Therapy 
Tyrosine kinase inhibitors (TKIs) have transformed the natural history of CML by 
inducing cytogenetic and molecular responses in the majority of patients in chronic 
phase resulting in transient deep responses in many cases of advanced disease. [26] 
Currently, there are three commercially available TKIs for the treatment of CML; 
these include Imatinib, Dasatinib, and Nilotinib. 
 
Imatinib was the first-choice treatment in CML with excellent results. It is a 2-
phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of 
tyrosine kinase enzymes. Imatinib mesylate is a tyrosine kinase inhibitor (TKI) that 
inhibits the BCR-ABL tyrosine kinase.It inhibits proliferation and induces apoptosis in 
BCR-ABL positive cell lines as well as fresh leukemic cells from Ph+ CML. Imatinib 
also inhibits the receptor tyrosine kinases for platelet derived growth factor (PDGF) 
and stem cell factor (SCF) called c-kit. Imatinib was identified in the late 1990s by Dr 
Brian J. Druker. Its development is an excellent example of rational drug design. 
Soon after identification of the BCR-ABL target, the search for an inhibitor began.  
Dasatinib and Nilotinib are considered a "second-generation" BCR/ABL tyrosine 
kinase inhibitors, built on the success of imatinib. Like Imatinib mesylate, Nilotinib 
bind the inactive conformation of BCR-ABL, although Nilotinib binds with a higher 
affinity. In contrast, Dasatinib binds the active conformation of BCR-ABL kinase and 
is a less selective kinase inhibitor targeting Src kinase family members as well. They 
are more potent inhibitors compared with Imatinib mesylate and show activity against 
most of the well characterized BCR-ABL mutants. Indeed, after more than one 
decade of clinical trial appling Imatinib as front line therapy for patients with CML, it is 
well known that TKI is not able to eradicate leukemia, and primary or secondary drug 
resistance eventually occurs in the first two years of treatment. Thus, new drugs with 
ever-increasing specificity and anti-leukemia power are always under investigation by 
researchers.   
 
New Alternative Drug Therapy in Leukemia 
The mechanisms underlying persistence of LSC in Imatinib-treated CML patients are 
not well understood. Although reduced drug uptake or increased efflux together with 
high levels of BCR-ABL expression in primitive progenitors could theoretically 
contribute to Imatinib resistance, previous studies have found adequate drug levels 
and effective inhibition of BCR-ABL activity in CML progenitors following Imatinib 
treatment. Several studies show also that Imatinib effectively inhibits proliferation of 
CML primitive progenitors but only modestly increases progenitor cell apoptosis. 
Growth factor (GF) or other microenvironmental signals may preserve viability of 
CML cells despite BCR-ABL kinase inhibition by Imatinib. Importantly Imatinib-
induced apoptosis is restricted to dividing CML progenitors, whereas non-dividing 
CML progenitors are especially insensitive to Imatinib-induced apoptosis. The 
relative insensitivity of non-dividing CML progenitors may contribute to the 
persistence of BCR-ABL positive progenitors in patients achieving remission during 
Imatinib therapy. Similar results have been obtained with more potent BCR-ABL TKI 
including Dasatinib, Nilotinib and Bosutinib. These results suggest that BCR-ABL 
independent mechanisms contribute to survival of primitive CML cells after TKI 
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treatment, and indicate the need to identify additional strategies to eliminate CML 
LSC. 
Since the discovery of the BCR-ABL kinase inhibitor Imatinib, great advances have 
been made in developing kinase inhibitors with exquisite selectivity and potency. 
Most of the drug discovery efforts on the identification of kinase inhibitors have been 
focused on ATP-mimetic small molecule inhibitors. Given that janus kinase (JAK2) is 
a tyrosine kinase, the discovery of activating mutations naturally resulted in a great 
deal of excitement and optimism in identifying and developing JAK2 inhibitors for the 
treatment of myeloproliferative neoplasms. JAK2V617F–mutated enzyme is often 
compared to the BCR-ABL oncoprotein from the standpoint of drug development. 
However, because no known vital function for endogenous ABL kinase has been 
identified, BCR-ABL inhibitors can be administered at doses that completely inhibit 
BCR-ABL and eliminate BCR-ABL–positive cells without concerns for mechanism 
related adverse effects. In contrast, it is important to recognize that because of the 
localization of the V617F mutation in a region outside the ATP-binding pocket of 
JAK2 enzyme, ATP-competitive inhibitors of JAK2 kinase are not likely to distinguish 
between wild-type and mutant JAK2 enzymes. Therefore, JAK2 inhibitors, by virtue 
of their near equipotent activity on wild-type JAK2, which is important for normal 
hematopoiesis, should have adverse myelosuppression as an expected side effect if 
administered at doses that aim to completely inhibit the mutant JAK2 enzyme. While 
they may prove to be effective at controlling hyper-proliferation of hematopoietic 
cells, they may not be able to eliminate mutant clones in a manner similar to BCR-
ABL inhibitors. On the other hand, JAK inhibitors may have great therapeutic benefit 
by controlling the disease for patients with myeloproliferative neoplasms who suffer 
from debilitating signs (eg, splenomegaly) or constitutional symptoms that 
presumably result from high levels of circulating cytokines that signal through JAK 
enzymes.  
Ruxolitinib (also known as INC424 or INCB18424) is an orally bioavailable, potent, 
and selective inhibitor of JAK1 and JAK2 that is approved for the treatment of 
intermediate and high-risk myelofibrosis. Ruxolitinib selectively inhibits the 
proliferation of JAK2 V617F-driven Ba/F3 cells, and these effects are correlated with 
decreased levels of phosphorylated JAK2 and of STAT5 [77]. 
Histone deacetylase inhibitors (HDACi) are a class of agents that have shown 
promise as a therapy for several cancers [78]. HDACi can modulate gene expression 
through increased histone lysine acetylation. Anti-cancer effects may also be related 
to modulation of the acetylation status of non-histone proteins. In contrast to most 
other pro-apoptotic agents that preferentially target dividing cells, HDACi have been 
shown to induce apoptosis in non-proliferating cancer cell lines, which may have 
important implications for elimination of quiescent primitive LSC. Several clinical trials 
for patients affected by myeloproliferative neoplasms are based on Panobinostat, a 
new anti-cancer drugs within the family of deacetylase inhibitors (HDACi) with a 
marked anti-tumor activity across a broad range of cancer cell lines of hematologic 
malignancies. It has been demonstrated to be effective in several neoplastic disease, 
including cutaneous T cell lymphoma (CTCL), acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML), multiple myeloma (MM), Hodgkin lymphoma (HL), as well 
as solid tumors cell lines such as breast, colon, prostate and pancreas. Treatment 
with the hydroxamic acid analog Panobinostat-HDACi SAHA, LAQ824 (LAQ) or 
LBH589 (LBH), alone and in combination with TKI has been reported to induce 
apoptosis in CML cell lines and BC CML.   
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The Role of Bone Marrow in CML 
The bone marrow microenvironment facilitates the survival, differentiation and 
proliferation of hematopoietic cells. These cells are supported by fibroblast-like bone 
marrow stromal cells, osteoblasts, and osteoclasts which secrete soluble factors and 
extracellular matrix proteins that mediate these functions. This rich environment 
serves as a safe haven not only for normal and malignant hematopoietic cells, but 
also for epithelial tumor cells that metastasize to bone, offering protection from 
chemotherapeutic agents by common mechanisms. Soluble factors produced in the 
bone marrow, such as stromal SDF-1 and IL-6, mediate homing, survival, and 
proliferation of tumor cells, and integrin-mediated adhesion sequesters tumor cells to 
this protective niche. Environment-mediated drug resistance includes a combination 
of soluble factors and adhesion, and can be subdivided into soluble factor mediated 
drug resistance and cell adhesion mediated drug resistance. Strategies to overcome 
BM stroma-mediated drug resistance should include not only disrupting the 
interaction between the CML cells and the BM stromal cells, but also, inhibit the 
signaling pathways mediated by cytokines and growth factors in the BM. Signals 
derived from the BM stroma can effectively reconstitute the downstream signaling 
pathway of BCR-ABL protein, such that CML cells can achieve BCR-ABL 
independent growth in the BM, making them resistant to BCR-ABL tyrosine kinase 
inhibitors.
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AIM OF THE STUDY 
 
BCR-ABL kinase inhibitors have provided proof of principal that targeted therapy 
holds great promise for the treatment of leukemia. However, despite the success of 
these agents in treating CML, the majority of patients continue to present Ph+ cells 
residing  within the BM microenvironment. These clinical observations suggest that 
the BM microenvironment may provide survival signals that contribute to the 
treatment failure in eliminating minimal residual disease. Experimental evidence 
indicates that exposure of tumor cells to either BM derived soluble factors or the 
extracellular matrix can confer a multi-drug resistance phenotype. Strategies to 
overcome BM stroma-mediated drug resistance should include not only disrupting 
the interaction between the CML cells and the BM stromal cells, but also, inhibiting 
the signaling pathways mediated by cytokines and growth factors in the BM.  
In this work, we evaluate whether the stromal microenvironment influence the drug 
resistance in CML, and whether we may suppress this resistance when in vitro 
leukemia cell line and CML progenitors are co-cultured in the presence of both 
stroma-derived supernatant or  stromal cell line. 
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MATERIALS AND METHODS 
 
Cell Cultures and tumor cells 
K562 cell line 
 
K562 is an erythroleukemia cell line derived from a chronic myeloid leukemia patient 
in blast crisis (obtained from the American Type Culture Collection).  The cell 
population has been characterized as highly undifferentiated and of the granulocytic 
series. The morphology is round large, single cells in suspension. Cells carry the 
BCR-ABL1 e14-a2 (b3-a2) fusion gene. Human CML K562 cells were cultured in 
RPMI supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine (L-Glu), 
and 1% penicillin/streptomycin (P/S), defined as regular media (RM),  at 37°C in 5% 
CO2 in a humidified incubator. K562 cells were kept at 0.5 x 10
6 cells/ml. 
KT1 cell line 
KT1 (CML) kindly provided by Dr Fujita (First Department of Internal Medicine, 
School of Medicine, Ehime University, Japan) is a leukemia cell line established from 
a patient in the blast crisis phase of CML. KT-1 has undifferentiated morphology that 
exhibited a high nuclear/cytoplasm ratio without cytoplasmic granules. KT-1 cells 
showed two Ph1 chromosomes and an absence of normal copies of chromosomes 9 
and 22. The KT-1 cells are IFN-alpha or IFN-gamma sensitive. Human CML KT1 
cells were cultured in RPMI supplemented with 10% fetal bovine serum (FBS), 1% L-
glutamine (L-Glu), and 1% penicillin/streptomycin (P/S), defined as regular media 
(RM), at 37°C in 5% CO2 in a humidified incubator. K562 cells were kept at 0.5 x 10
6 
cells/ml. 
BV173 cell line 
BV173 (obtained from Leibniz Institute DSMZ-German Collection of Microorganisms 
and Cell Cultures) is a B cell precursor leukemia cell line established from the 
peripheral blood of a 45-year-old man with chronic myeloid leukemia (CML) in blast 
crisis in 1980. The morphology of cell is round to elongate. Cells grow in suspension. 
Cells carry the t(9;22) leading to BCR-ABL1 e13-a2 (b2-a2) fusion gene. Human 
BV173 cells were cultured in RPMI supplemented with 20% FBS, 1% L-Glu and 1% 
P/S, defined as regular media (RM),  at 37°C in 5% CO2 in a humidified incubator. 
BV173 were maintained at 0.5 x 106 cells/ml. 
HS-5 cell line 
The human stromal cell line HS-5 (obtained from the American Type Culture 
Collection) is a fibroblastoid cell line immortalized by transduction with the human 
papilloma virus E6/E7 genes. Cells grow in adherent manner. it secretes detectable 
amounts of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), 
macrophage inhibitory protein 1-α, stem cell factor (SCF), leukemia-inhibitor factor, 
IL-11, IL-8, IL-6, and IL-1; and it is capable of sustaining proliferation of normal 
hematopoietic progenitors cells in serum-free media without additional growth 
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factors. Human HS-5 cell were cultured α- MEM supplemented with 10% FBS, 1% L-
Glu, and 1% P/S at 37°C in 5% CO2 in a humidified incubator. HS-5 cultured 1,5 × 
106 cells/mL to achieve 75% to 80% confluency. Subsequently, the medium was 
removed from the cells and was flirted with 0.22 µm filter for future use 
Samples from CML Patients and Healthy Donors 
Bone marrow samples and peripheral blood were collected from 20 newly diagnosed 
patients with CML-CP patients enrolled in our Institution and two healthy donors 
(HD), after signed informed consent was obtained in accordance with the Declaration 
of Helsinki and after approval by the Institutional Review Board (IRB) of University of 
Naples Federico II. 
 
Isolation of CML Progenitor Cells CD34+  
BM and PB samples were obtained from donors clinical protocol GIMEMA. 
Mononuclear cells were isolated using Ficoll separation. CD34+ cells were sorted 
with Miltenyi Biotec CD34 MicroBead Kit human. The CD34+ cells are magnetically 
labeled with CD34 MicroBeads. Then, the cell suspension is loaded onto a MACS® 
Column which is placed in the magnetic field of a MACS Separator. The magnetically 
labeled CD34+ cells are retained within the column. The unlabeled cells run through; 
this cell fraction is thus depleted of CD34+ cells. After removing the column from the 
magnetic field, the magnetically retained CD34+ cells can be eluted as the positively 
selected cell fraction. We resuspend cell pellet in 300 µL of buffer for up to 10⁸ total 
cells. We add 100 µL of FcR Blocking Reagent for up to 10⁸ total cells.  We add 100 
µL of CD34 MicroBeads for up to 10⁸ total cells and Mix well and incubate for 30 
minutes in the refrigerator (2−8 °C). After we re-suspended in 10ml of MACS 
BUFFER and centrifuged at 1000 rpm for 5 min and resuspended in 500µL in MACS 
BUFFER and proceed to magnetic separation. After they cultured media IMDM 10% 
FBS, 10% P/S. The CD34+ cells were cultured in AIM-V serum-free media 
(Invitrogen) supplemented with 2nM L-glutamine (GIBCO-BRL Invitrogen), 1% 
penicillin/streptomycin (Gibco-Invitrogen) at a starting density of 1x105 cells/ml at 
37°C, 5% CO2, in a humidified incubator for 4 days. When specified, the following 
cytokines were included [high grow factor (GF) cocktail]:100 ng/ml SCF, 100 ng/ml 
FLT3 ligand, 20 ng/ml G-CSF, 20 ng/ml IL-3, and 20 ng/ml IL-6 (all from R&D 
Systems). Depending on the individual experiment, TKI were added at approximely a 
clinical relevant concentration (1µM Imatinib, 400nM Nilotinib and 2.5nM Dasatinib). 
Generation of Mesenchymal Stroma Cell (MSC) and Mesenchymal Stroma 
Conditioned Media (SCM) 
Mononuclear cells were isolated from BM aspirates by centrifugation on a Ficoll-
Hypaque gradient. MSC cells were sorted with Miltenyi Biotec Anti MSCA-1 
MicroBead kit human. Briefly, the MSC+cells are magnetically labeled with MSC 
MicroBeads. Then, the cell suspension is loaded onto a MACS® Column which is 
placed in the magnetic field of a MACS Separator. The magnetically labeled MSC 
cells are retained within the column. The unlabeled cells run through; this cell fraction 
is thus depleted of MSC cells. After removing the column from the magnetic field, the 
magnetically retained MSC cells can be eluted as the positively selected cell fraction. 
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Human MSCA-1+ cells were cultured in Mesenchymal Stem Cell Basal Medium 
(MSCBM) with Mesenchymal Cell Growth Supplement (MCGS), 2% (L-Glu), 1% 
Penicillin/Streptomycin and cultured at 37°C in 5% CO2 in a humidified incubator. 
Conditioned Media (CM) was collected after at least two cell passages of two 
mesenchymaò stroma cell lines obtained from Healthy Donor (HD), named HD/SCM 
and eight stroma cell lines obtained each from a BM sample of a patient with CML, 
named CML/SCM, and stored at -80°C. After SCM collection, mesenchymal stroma 
cell lines have been immunophenotypically analyzed for the positive expression of 
CD73, CD90, and CD105 and negative for CD45, CD34, CD14 or CD11b, CD79α or 
CD19, and HLA-DR surface antigens (human MSC Phenotyping Kit, Miltenyi). 
 
The Trypan Blue Method: Assessment of Percentage of Viable and Non Viable Cells  
Cells were stained with trypan blue (Sigma, St Louis, MO). The reactivity of trypan 
blue is based on the fact that the chromopore is negatively charged and does not 
interact with the cell unless the membrane is damaged. Therefore, all the cells which 
exclude the dye are viable. The numbers of non-viable cells were determined by 
counting the cells that showed trypan blue uptake using the Burker’s chamber, and 
reported as percentage of untreated control cells. 
 
Drugs and Reagents 
Imatinib mesylate and Nilotinib, both supplied by Novartis Pharma, were dissolved in 
DMSO as a 10 mmol/L stock solution and stored in aliquots at −20°C. Dasatinib, 
supplied by Bristol-Myers Squibb, was treated similarly. Panobinostat and Roxolitinib 
. 
Apoptosis Assay 
Apoptosis was measured using FITC Annexin V Apoptosis Detection Kit II BD 
Pharmingen. Briefly, we wash cells twice with cold PBS and then resuspend them in 
1X Binding Buffer at a concentration of 1 x 10^6 cells/ml. We transfer 100 µl of the 
solution (1 x 10^5 cells) to a 5 ml culture tube and add 5 µl of FITC Annexin V and 5 
µl propidium iodide (PI). We gently vortex the cells and incubate for 15 min at RT 
(25°C) in the dark. After incubation we add 400 µl of 1X Binding Buffer to each tube. 
Analyze by flow cytometry within 1 h. 
In apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane, thereby 
exposing PS to the external cellular environment. FITC Annexin V is a 35-36 kDa 
Ca2+ dependent phospholipid-binding protein that has a high affinity for PS, and 
binds to cells with exposed PS. Since externalization of PS occurs in the earlier 
stages of apoptosis, FITC Annexin V staining can identify apoptosis at an earlier 
stage than assays based on nuclear changes such as DNA fragmentation. FITC 
Annexin V staining precedes the loss of membrane integrity which accompanies the 
latest stages of cell death resulting from either apoptotic or necrotic processes.  
Therefore, staining with FITC Annexin V is typically used in conjunction with a vital 
dye such as propidium iodide (PI) or 7-Amino-Actinomycin (7-AAD) to allow the 
investigator to identify early apoptotic cells (PI negative, FITC Annexin V positive).  
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PI is an intercalating agent and a fluorescent molecule with a molecular mass of 
668.4 Dalton that can be used to stain cells. Propidium iodide is used as a DNA stain 
for both flow cytometry to evaluate cell viability or DNA content in cell cycle analysis 
and microscopy to visualize the nucleus and other DNA containing organelles. It can 
be used to differentiate necrotic, apoptotic and normal cells.  
Viable cells with intact membranes exclude PI, whereas the membranes of dead and 
damaged cells are permeable to PI. Cells that are considered viable are FITC 
Annexin V and PI negative; cells that are in early apoptosis are FITC Annexin V 
positive and PI negative and cells that are in late apoptosis or already dead are both 
FITC Annexin V and PI positive.  
 
Flow-Cytometric Assays 
Apoptosis was measured using FITC Annexin V Apoptosis Detection Kit II (BD 
Pharmingen). The percentage of apoptotic cells was determined by flow cytometry. 
Cell cycle analysis was detrmined by BRdU Flow Kits (BD Pharmigen), as specified 
by the manufactory. 
 
Analysis of Proliferation  
The immunofluorescent staining of incorporated bromodeoxyuridine (BrdU) and flow 
cytometric analysis provide to determine the frequency and nature of individual cells 
that have synthesized DNA. In this method, BrdU (an analog of the DNA precursor 
thymidine) is incorporated into newly synthesized DNA by cells entering and 
progressing through the S (DNA synthesis) phase of the cell cycle. The incorporated 
BrdU is stained with specific anti-BrdU fluorescent antibodies. The levels of cell-
associated BrdU are then measured by flow cytometry. Often, staining with a dye that 
binds to total DNA such as 7-aminoactinomycin D (7-AAD) is coupled with 
immunofluorescent BrdU staining. With this combination, two-color flow cytometric 
analysis permits the enumeration and characterization of cells that are actively 
synthesizing DNA (BrdU incorporation) in terms of their cell cycle position (ie, G0/1, 
S, or G2/M phase defined by 7-AAD staining intensities). The kit used is BRdU Flow 
Kits of Bd Pharmigen. 
 
Evaluation of BCR-ABL Activity in K562 Cell Line 
K562 cell have been treated with TKIs at the indicated concentration for 30’ (minute), 
than cells were transferred in ice and washed with cold PBS. To simultaneously 
asses the phosphorylation status of BCR-ABL target, we carried out 
intracytoplasmatic immunostaining with antibody against p-CrkL (Tyr207), p-STAT5 
(Tyr694), p-ERK1/2 (Thr202/Tyr204) and p-STAT3 (Tyr705) (Cell Signaling 
Technology), following the manufacturer’s instructions. For each sample, a minimum 
of 100,000 cells were analyzed using a FACSCalibur (Becton Dickinson, San Diego, 
CA). 
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Colony-Forming Unit (CFU) Inhibition Assay of Leukemic and Normal Hematopoietic 
Progenitors 
CD34+ cells are prepared by positive selection using Miltenyi Biotec CD34 
MicroBead Kit human. After the count is made with 3% acetic acid. We prepare a 
10X concentrated cell suspension of cells in IMDM with 2% FBS. Add 0.3 mL of cells 
to 3 mL of MethoCult. This 1:10 v/v ratio of cells:medium gives the correct viscosity to 
ensure optimal CFC growth and morphology. We vortex tube to mix contents 
thoroughly and then let stand for 2 - 5 minutes to allow bubbles to dissipate before 
dispensing and using a 3 mL syringe attached to a 16 gauge blunt-end needle, 
dispense 1.1 mL of the MethoCult mixture containing cells into a 35 mm dishes. 
Gently  we tilt and rotate each dish to distribute methylcellulose evenly. Dishes are 
pre-screened to ensure low cell adherence. Cell adherence can inhibit CFC growth. 
Finally we add 3 - 4 mL of sterile water to an additional uncovered 35 mm dish. For 
duplicate assays, place all three dishes into a 100 mm culture dish. The cells are 
incubate at 37°C, in 5% CO2, with 95% humidity for 14 - 16 days. 
 
High Grow Factor Cocktail 
We used the same high grow factor cocktail reported by Susan M. Graham et al; 
Briefly, CD34+ cells were grown in Iscoves modified Dulbecco medium (Sigma) 
supplemented with a serum substitute (BIT; StemCell), supplemented or not with 
100ng/mL recombinant human Flt3-ligand (Immunex Corporation, Seattle,WA) and 
Steel factor (Terry Fox Laboratory, Vancouver, BC, Canada), and with 20 ng/mL 
recombinant human interleukin-3 (IL-3) (Novartis, Basel,Switzerland), IL-6 (Cangene, 
Mississauga, ON, Canada), and granulocyte–colony-stimulating factor (G-CSF) 
(Chugai Pharma, United Kingdom; abbreviated as 5 growth factors [GFs], like 
reported by Susan M. Graham et al.)  
 
Half Maximal Inhibitory Concentration (IC 50) 
IC50 is a measure of the effectiveness of a compound in inhibiting biological or 
biochemical function. This quantitative measure indicates how much of a particular 
drug or other substance (inhibitor) is needed to inhibit a given biological process (or 
component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. 
In other words, it is the half maximal (50%) inhibitory concentration (IC) of a 
substance (50% IC, or IC50). It is commonly used as a measure of antagonist drug 
potency in pharmacological research.  
To calculate the IC50 based on the level of viable cells after TKI treatment in the 
presence or absence of  HS-5/CM, we analyzed our data by a specific software 
(MasterPlex ReaderFit), applying 4 Parameter Logistic (4-PL) and 5 Parameter 
Logistic (5-PL) model equations to calculate IC50 for dose response curves. 
 
 
33 
 
Q-RT-PCR 
Single cell clones have been evaluated for the expression of P210 mRNA by 
quantitative real-time PCR (Q-RT-PCR) as previously described. Briefly, all 
amplification reaction was carried out in triplicate and the mean Ct value was used to 
interpolate standard curves and calculate the transcript copy number. 
 
Bioplex ELISA Assay 
The Bio-Plex multiplex system enables the detection and quantification of multiple 
analytes in a single sample volume. Utilizing xMAP technology licensed from 
Luminex, the Bio-Plex Multiplex system can multiplex up to 500 different assays 
simultaneously. We evaluated the secretory profiles between the HS5/SCM and  
CML/SCM from 8 mesenchymal stromal cell lines obtained from CML patient, in 
particular we tested them for 20 different analytes, reported to be involved in 
leukemia signaling pathways: IL-1a, IL-3, M-CSF, SCF, SDF1-a, TRAIL, HGF, 
PDGF-bb, IL1b, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, G-CSF, GM-CSF, MIP-1a, TNF-a, 
and VEGF; using the Bio-PLEX-200 System. 
 
Statistical Analysis 
All in vitro experiments were summarized as mean plus or minus one standard 
Deviation (SD). Student t test was used to determine the statistical significant 
differences by non parametric Mann-Whitney test, between values obtained in a 
population of leukemic cells treated with different experimental conditions, with P 
value less than .05 indicating a significant difference. The half maximal inhibitory 
concentration (IC50) was calculated based on the level of viable cells (Annexin-
Vneg.ve/PIneg.ve) residual after treatment with increasing doses of TKI ranging from 0 to 
100µM in the presence or absence of HS-5/SCM. Data were analyzed by a specific 
software (MasterPlexReaderFit), applying 4 Parameter Logistic (4-PL) and 5 
Parameter Logistic (5-PL) model equations to calculate the IC50 for dose response 
curves. Combination index (CI), defined as quantitative measure of the degree of 
drug interaction in terms of synergism and antagonism for a given endpoint of the 
effect measurement [Z=(1-T/V), calculated from drug-treated samples with a 
measured response T (as a percentage of residual viable cells; Annexin- 
Vneg.ve/PIneg.ve) relative to V, (a median level of viable cells of 10 vehicle-treated 
samples),[81] was calculated by CompuSyn software based on Chou’s median-effect 
equation and its extension, combination index (CI) equation.  
In particular, based on the CI value, we defined, as previously reported, a very strong 
synergism (CI<1), strong synergism (0.1-0.3), synergism (0.3-0.7), moderate 
synergism (0.7-0.85), slight synergism (0.85-0.9), nearly additive (0.90-1.10), slight 
antagonism (1.10-1.20), moderate antagonism (1.20-1.45), antagonism (1.45-3.3), 
strong antagonism (3.3-10) and very strong antagonism (>10).  
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RESULTS 
 
Evaluation of the BM microenvironment activity on the modulation of TKI-induced 
apoptosis in BCR-ABL+ cell line. 
To evaluate whether BM microenvironment has a potential role on modulation of first 
and second generation TKI activity on Ph+ cells, we treated K562, BV173 and KT1 
cell lines with Imatinib, Nilotinib or Dasatinib at clinical relevant concentrations, in the 
presence of monolayer human stromal cell line HS-5. 
Ph+ cell lines are incubated in direct contact of HS-5 or in the presence of 
supernatant derived from HS-5 culture; they are significantly protected from TKI-
related cell apoptosis (Fig.4A-C) and mortality (Fig.5A-C). 
Indeed, when K562 cell line (Figure 4A) are treated with Imatinib, Nilotinib or 
Dasatinib in the presence of a HS-5 monolayer, apoptosis is significantly reduced 
(18%±13%, 50%±6%, or 10%±10%, respectively), respect to Ph+ cell line treated in 
Regular Media (RM) (46%±12%, 84%±15%,  or 53%±20%, respectively. p<0.05 in all 
the conditions. (Figure 4A). Similar results have been achieved in the context of 
BV173 and KT1 cell lines (Figure 5A and 5B). Moreover, we demonstrated that TKI-
resistant is also related to soluble factors produced by HS-5 in the conditioned media 
(HS-5/SCM). Indeed, a significant level of protection is also achievable by treating 
Ph+ cells with TKIs in the presence of HS-5/SCM soluble factors (Figure 4A-C dark-
gray barrel).  
The apoptosis is also greatly reduced when K562 cell line is treated with Imatinib, 
Nilotinib or Dasatinib in the presence of HS-5/SCM (20%±9%, 29%±18%, or 
17%±6%, respectively), respect to Ph+ cell line treated in RM.   
To evaluate if the observed stroma-related TKI resistance is merely associated to 
HS-5 intrinsic characteristics, we generated stromal cell lines directly from two 
healthy BM donor identified as healthy donor/stroma cells (HD/SC) and 8 patients at 
diagnosis affected by CML identified as CML/ stroma cells (CML/SC) by the sorting 
MSCA1+ BM cells and after the second passage, we collected conditioned media 
from stroma cell culture. 
We tested the effects of the derived conditioned media obtained from these stroma 
cell lines (HD/SCM and CML/SCM, respectively) on the regulation of TKI activities on 
Ph+ cell lines. As shown in Figure 4A-C, HD/SCM (white barrel) and CML/SCM (gray 
barrel) are equally able to significantly reduce TKI-related apoptosis in K562 (Figure 
4A), KT1 (Figure 4B) or BV173 cell lines (Figure 4C). Indeed TKI-induced apoptosis 
is significantly inhibited in K562 cell line by CML/SCM exposition (22%±12%, 
40%±16%, or 31%±16%, respectively) respect to control cell line treated in RM 
(46%±12%, 84%±15%, or 53%±20%, respectively. (Figure 4A). p<0.05 in all the 
conditions. Similarly, apoptosis was greatly reduced when KT1 and BV173 cell lines 
were treated with TKIs in the presence of HD/SCM or CML/SCM (Fig. 4B and 4C, 
respectively).  
Thus, we demonstrated that BM mesenchymal stroma microenvironment, either 
represented by the selected clone HS-5 or by mesenchymal stroma cell lines derived 
from HD and CML patients, provides survival factor able to protect Ph+ cells from 
TKI-related apoptosis or cell death.  
 
35 
 
 
 
Figure 4. Analysis of Imatinib, Nilotinib and Dasatinib activity modulation by 
Mesenchymal Stroma cells exposition.  
Ph+CML cell lines, K562, BV173 and KT1 were treated with the indicated 
concentrations of Imatinib, Nilotinib or Dasatinib in different culture conditions: in 
regular media (RM) (black barrel), in the presence of a HS-5 monolayer (light-gray 
barrel), in media supplemented with 50%  of HS-5/SCM (dark-gray barrel), in media 
supplemented with 50% of HD/SCM (white barrel), or in media supplemented with 
50% of patients derived CML/SCM (gray barrel). Apoptosis were monitored by 
Annexin V/PI staining after 24 hrs in K562 cell line (A), KT1 cell line (B) and BV173 
cell line (C). Results represent the mean ± SD from 3 independent experiments. 
p<0.01 for all the condition. IC50 was calculated based on the level of viable cells 
(Annexin-Vneg.ve/PIneg.ve) residual after treatment with increasing doses of Imatinib (D), 
Nilotinib (E) or Dasatinib (F) ranging from 0 to 100.000nM in the presence 
(continuous line) or absence (dot line) of HS-5/SCM.   
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Figure 5. Cell viability in Ph+ cell lines treated with TKI upon Mesenchymal 
Stroma cells exposition.  
Ph+CML cell lines, K562, BV173 and KT1 were treated with the indicated 
concentrations of Imatinib, Nilotinib or Dasatinib in different culture conditions: in 
regular media (RM) (black barrel), in the presence of a HS-5 monolayer (light-gray 
barrel), in media supplemented with 50%  of HS-5/SCM (dark-gray barrel), in media 
supplemented with 50% of HD/SCM (white barrel), or in media supplemented with 
50% of patients derived CML/SCM (gray barrel). Cell viability were monitored by 
Annexin V/PI staining after 72hrs, in K562 cell line (A), KT1 cell line (B) and BV173 
cell line (C). Results represent the mean ± SD from 3 independent experiments. 
Significance values: * p<0.05; ** p<0.01.  
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Half Maximal Inhibitory Concentration (IC 50) of TKI 
To quantify the effect of HS-5/SCM exposition on TKI activity, K562 cell line has been 
treated with an escalation dose of Imatinib, Nilotinib or Dasatinib (range 0.1-100,000 
nM) in the presence or in the absence of HS-5/SCM. Cellular viability has been 
monitored after 72hrs. by Annexin-V/IP flow cytometric test and for cell viability 
estimating the number of PI negative cells. 
We demonstrated that the IC50 of Imatinib, Nilotinib or Dasatinib is significantly 
increased when the Ph+ cell line K562 is cultured in the presence of HS-5/SCM 
(5309.29nM, 381.14nM, 2.31nM, respectively) vs the IC50 calculated on K562 viable 
cells residual after TKI treatment in RM (564.97nM, 14.26nM and 1.13nM, 
respectively).  
In particular the IC50 of K562 cell line, based on cell viability at 72hrs after Imatinib 
treatment, increases about ten times from 564.97 nM in RM to 5309.29 nM in cell 
treated in presence of HS-5/SCM (Fig.6A), the IC50 increases about thirty times from 
14.26 nM in RM to 381.14 nM  in HS-5/SCM after Nilotinib treatment and the IC50 
increases about  two times from 1.13 nM in RM to 2.31 nM in HS-5/SCM, after 
Dasatinib treatment. Moreover, in average 47%, 40% and 51% of K562 cells 
exposed to HS-5/SCM were still viable after treatment with 3000nM Imatinib, 300nM 
Nilotinib or 3nM Dasatinib, respectively (11%, 15% and 17% of K562 cells treated 
with the same concentration of TKIs in the absence of HS-5/SCM (Fig.5A); p<0.001 
in all the conditions). Similarly, we observed the same results when KT1 and BV173 
cell lines were exposed to HS-5/SCM. (Fig.5B and 5C, respectively). 
Finally, to evaluate whether the viable Ph+ cells residual after TKI treatments in the 
presence of HS-5/SCM are able to further expand or apoptosis is just delayed by the 
presence of soluble factors produced by stroma cell line, we cultured K562 cell line 
with TKIs at the calculated IC50 (Table 1) for 72 hrs in the presence of HS-5/SCM.  
Cells were collected and re-plated in complete media for a total of 14 days without 
addition of TKIs. As shown in Fig 8A, residual K562 cells after TKIs treatment upon 
stroma exposition were able to significantly expand after drug withdrawal, respect to 
K562 cells exposed to a single dose of TKIs in the absence of HS-5/SCM.  
However, HS-5/SCM withdrawal before TKI treatment is able to completely overcome 
the stroma-mediated TKI protection (Fig 8B). Moreover, serial dilutions of HS-5/SCM, 
ranging from 50% to 0.05%, show that soluble factors are associated to stroma-
related TKI resistance in a dose dependent manner (Fig.8C). 
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Table1. IC50 modulation in K562 cell line by stroma conditioned media. 
Data were analyzed by specific software (MasterPlex ReaderFit), applying 4 
Parameter Logistic (4-PL) and 5 Parameter Logistic (5-PL) model equations to 
calculate IC50 for each dose response curve. 
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Figure 6: K562 cell line was evaluated for cell viability after 72hrs of treatment 
by Annexin-V/IP flow cytometric test and by estimating the number of PI 
negative cells. A) IC50 based on cell viability at 72hrs after Imatinib treatment : IC50 
CNT= 564.97 nM; IC50 HS-5/CM=5309.29 nM; B) IC50 based on cell viability at 
72hrs after Nilotinib treatment: IC50 CNT= 14.26 nM; IC50 HS-5/CM=381.14 nM C) 
IC50 based on cell viability at 72hrs after Dasatinib treatment: IC50 CNT= 1.13 nM; 
IC50 HS-5/CM=2.31 nM 
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Figure 7: K562 cell line was evaluated for apoptosis induction after 72hrs of 
treatment by Annexin-V/IP flow cytometric test. A) IC50 based on cell viability at 
72hrs after Imatinib treatment: IC50 CNT= 564.97 nM; IC50 HS-5/CM=5309.29 nM; 
B) IC50 based on cell viability at 72hrs after Nilotinib treatment: IC50 CNT= 14.26 
nM; IC50 HS-5/CM=381.14 nM C) IC50 based on cell viability at 72hrs after 
Dasatinib treatment: IC50 CNT= 1.13 nM; IC50 HS-5/CM=2.31 nM. 
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Figure 8A. Residual number of K562 cells after TKIs treatment upon stroma 
exposition were able to significantly expand after drug withdrawal. Cell 
proliferation has been monitored by trypan blu exclusion methode at the indicated 
time point. Long viability experiment: K562 cell line was treated with 5µM Imatinib 
(red square), 400nM Nilotinib (green triangle) and 2.5nM Dasatinib (black rhombus) 
at time 0 and day 3, day 7 and day 14 in RM (continuous lines) or HS-5/SCM (dotted 
lines).  
Figure 8B. HS-5 media withdrawal before TKI treatment doesn't not protect 
from TKI induced apoptosis. K562 cell line was treated with 4000nM Imatinib at 
time 0 in RM or presence of HS-5/SCM. Cell viability (dark gray barrel) and apoptosis 
(light gray barrel) were monitored by Annexin-V/PI staining after 72hrs of treatment.  
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Figure 8C. SCM protects K562 cell line from apoptosis in a dose dependent 
manner.  K562 cell line was evaluated for cell viability, by Annexin-V/PI staining after 
72hrs of TKI treatment, in cell culture conditions where media was supplemented 
with increasing percentage of HS5/SCM. (N=3. * indicates p<0.005). 
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Analysis of Cell Proliferation in Ph+ Cells treated with TKI in the presence of Stromal 
Microenviroment. 
It has been reported that Ph+ quiescent staminal cells are not sensible to TKI-
induced apoptosis. Thus, to evaluate if stroma conditioned media protect Ph+ cells 
from TKI-induced apoptosis by reducing cell cycle induction, we treated K562 cells 
with Imatinib, Nilotinib or Dasatinib at the calculated IC50, either in the presence or 
absence of HS-5/CM. Thus, cell line was evaluated for cell proliferation after 24hrs of 
treatment by Bromo Uridine (BrdU) assay. Direct measurement of new DNA 
synthesis by using nucleoside analogs is a well established method. BrdU flow kit, 
based on the incorporation of BrdU into newly synthesized DNA strands of actively 
proliferating cells, is the method of choice compared to traditional 3H-thymidine 
incorporation assays, which are slow, labor intensive, and involve hazardous 
radioactive materials. When BrdU incorporation assays are combined with DNA dyes 
such as 7-aminoactinomycin D (7-AAD), it is possible to resolve cell cycle phases in 
a given cell population into G0/G1, S, and G2/M phases using flow cytometry. 
As shown in Figure 8D, HS-5/CM did not significantly modify the percentage of K562 
cell line in the G0-G1 cell cycle phase. Moreover, Imatinib, Nilotinib and Dasatinib 
treatment induced a significant increase in G0-G1 cell cycle phase, in a HS-5/CM 
independent manner. Indeed TKI treatment significantly increased the G0-G1 fraction 
of K562 cells and decreased proportion of S-phase cells compared with the untreated 
cells. Because most available chemotherapeutic agents show some degree of S-
phase specificity, cells that are not actively dividing may prove resistant to such 
drugs. The quiescent leukemic cells are likely to survive to standard chemotherapy 
regimens, and it may explain the clinical observation that, unlike CML cannot be 
eradicated by TKI chemotherapy alone. 
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Figure 8D: TKI treatment significantly induce G0-G1 cell cycle arrest in Ph+ cell 
line independently by HS5/SCM. The K562 cell cycle state was evaluated after 
24hrs of TKI treatment by BrdU assay. The graphic show the percentage of K562 cell 
line in the G0-G1 phase (black barrel); the percentage of K562 cell line in the G2-M 
(gray-white barrel) and the percentage of K562 cell line in the S-phase (gray-iron 
barrel).  
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CML derived BM mesenchymal cell lines produce several STAT3 activating cytokines 
 
TKI treatment effect was not modified in the K562 cell line by the presence of HS-
5/SCM, despite the effective inhibition of BCR-ABL kinase activity. Indeed, Imatinib 
(500nM), Nilotinib (15nM) or Dasatinib (1.5nM) treatment was able to reduce the 
phosphorylation level of the considered BCR/ABL targets as CkrL, STAT5 and ERK 
in Ph+ cells when cultured in either RM or in the presence of HS-5/SCM (Fig.9A-C 
respectively). In contrast, STAT3-Y705 was detected at the activated level in K562 
cell line only when the cell line was exposed to HS-5/SCM, independently of TKI 
treatments (Fig. 9D), as previously reported. Constitutively active STAT3 induces the 
expression of anti-apoptotic genes including Bcl-2, Bcl-xl, Mcl-1, and also up-
regulates the expression of inhibitors of apoptotic machinery like survivin and c-IAP2. 
Since, STAT3 has been demonstrated to be activated by a variety of cytokine 
receptors including G-CSF and members of the IL-3/IL-5/GM-CSF family. We also 
quantified by Bioplex ELISA assay the amount of several cytokines known to be 
related to survival signaling, in HS-5/SCM and CML/SCM derived from 8 BM 
mesenchymal stromal cell lines generated from BM samples of 8 patients affected by 
CP-CML. As shown in Figure 10, the majority of the cytokines are present at a 
significant higher level in HS-5/SCM than in CML/SCM (IL-1a, M-CSF, SCF, PDGF-
bb,  IL-1b, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, G-CSF, GM.CSF, MIP-1a, TNF-a and 
VEGF), whereas SDF-1a, TRAIL and HGF cytokines are present in HS-5/SCM and 
CML/SCM supernatants at similar levels. As already observed IL-3 was not found in 
any supernatant but not in one single tested CML/SCM at the concentration of 
9pg/ml. Interesting we observed that both cell lines HS-5/SCM and CML/SCM 
produce high level of cytokine IL-6 which serves as a positive feedback loop to 
sustain CML development and acts at the level of leukemic MPPs (CML multipotent 
progenitors cells) to promote myeloid development at the expense of lymphoid 
differentiation. IL-6 is a major player in CML pathogenesis. Indeed BCR/ABL 
regulates IL-6 mRNA levels through a complex and indirect mechanism involving, at 
least, BCL6 and the LIN28/28b-Let-7 pathway, which are two known transcriptional 
regulators of the IL-6 gene. This paracrine mechanism appears exacerbated in CML 
myeloid blast crisis, most likely due to increased IL-6 production by blast cells. 
Pharmacological inhibition of BCR/ABL activity with TKIs in K562 cell line or in CML 
cells downregulate STAT5 activation  and both LIN28 and LIN28b expression, that 
increase BCL-6 expression, a direct transcriptional repressor of the IL-6 gene (Yu et 
al., 2005). Then exogenous IL-6 may activates the JAK-STAT pathway in CML 
CD34+ cells treated with TKIs. In our experiment we show that stroma cell lines 
producing high level of IL-6 may protect leukemic cell fate by TKI effect. 
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Figure 9. HS-5/CM phosphorylates STAT3 and confers BCR/ABL indipendent 
resistance against TKI treatment. K562 cells were treated with Imatinib (500nM), 
Nilotinib (15nM) or Dasatinib (1.2 nM) for 2.5 hours, and the extracts from these cells 
were subjected to immunoblot analysis for phosphorylated (p) or total forms of 
proteins (not showed) associated with the BCR/ABL signaling pathway. The 
immunoblot analyses were showed for p-CrKL (A), pSTAT5 (Tyr694) (B), p-ERK (C) 
and pSTAT3 (Tyr705) (D).  
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Figure 10. Bioplex ELISA assay. Comparation of secretory profiles between the 
HS5/SCM and CML/SCM.  The human bone marrow stromal cell line HS-5 or the 
mesenchymal stromal cell derived from 8 BM CML patients were seeded in 75-cm2 
flasks and grown to 70%–80% confluency. Thereafter, culture media were 
exchanged for in α-MEM supplemented with 20% FBS, 1% L-Glutamine, and 1% 
penicillin/streptomycin. After 24 hours, the conditioned medium was carefully 
harvested, centrifuged for 10 minutes at 5,000g to remove debris, 0.22 µm filtered 
and stored at -80°C before the Bioplex ELISA  analysis.  
 
 
  
 
48 
 
Ph+ Cell fate after TKI treatment in the Presence of Stroma-Derived Soluble Factor 
In our study, we attempted to evaluate whether the viable cells residual after TKI 
treatment in the presence of stroma derived media, were already death-committed or 
instead, they were capable of additional cell divisions. Thus, we treated K562 cells 
with Imatinib, Nilotinib or Dasatinib at the calculated IC50, either in the presence or 
absence of HS-5/CM. After 72hrs, cells have been re-plated in new fresh media 
without addition of TKI. Cell proliferation and cell viability have been monitored by 
Trypan blu exclusion every 3 days for two consecutive weeks. On day 3, cell 
proliferation was significantly reduced by Imatinib, Nilotinib and Dasatinib treatment 
in all control conditions, where K562 cells were cultured in the absence of stroma 
derived soluble factors. Moreover, at a TKI concentration clinically achievable, cell 
viability and proliferation of K562 cell line continue to decrease overtime, showing 
that Ph+ cell line may be completely eliminated. In contrast, HS-5/CM is able to 
reduce TKI activity as previously demonstrated, and viable K562 cells were also able 
to further expand even if exposed to high concentration of Imatinib, Nilotinib and 
Dasatinib. 
  
 
49 
 
 
Figure 11. Cell proliferation has been monitored  by Trypan blu exclusion at the 
indicated time point. A) Long viability experiment: K562 cell line was treated with 
1µM Imatinib (square), 30nM Nilotinib (rhombus) and 2nM Dasatinib (triangle) at time 
0 in the absence (continuous lines) or presence of HS-5/CM (dashed lines). B) Long 
viability experiment: K562 cell line was treated with 4µM Imatinib (square), 300nM 
Nilotinib (rhombus) and 10nM Dasatinib (triangle) at time 0 in the absence 
(continuous lines) or presence of HS-5/CM media (dashed lines).  
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CD34+ CML Progenitor Cells are Protected from TKI Toxicity by Stroma Conditioned 
Media and Cytokines 
We evaluate if the observed stroma derived TKI resistance may have some 
relevance also in a patient related setting. In particular, we selected haematopoietic 
progenitor cells from BM and peripheral blood samples of 10 untreated patients 
affected by CML, by sorting with a magnetic system CD34+ cells. 
The CD34+ cells were treated with clinical relevant concentration of TKIs, and drug-
related cell death and apoptosis have been monitored after 72 and 24hrs, 
respectively. As shown in Fig. 12A-B, and as already demonstrated by several other 
independent groups, immature CML CD34+ cells, grown in the absence of grow 
factors,  are inherently resistant to TKI treatment since 20±11%, 19±11% and 19±9% 
of CD34+ cells are still viable after treatment with Imatinib, Nilotinib or Dasatinib, 
respectively. 
Moreover, drug-related cell death and apoptosis are significantly reduced when CML 
CD34+ cells are treated with Imatinib, Nilotinib or Dasatinib in the presence of either 
high growth factor cocktail or HS5/SCM (Figure 12A-B). 
To confirm that the viable residual cells were not irreversible un-functional after TKI 
treatment, primary progenitor CML CD34+ cells residual after TKI treatment in the 
presence or absence of stroma derived grow factors, were washed and plated in a 
methylcellulose-based medium that is widely used to detect and quantify 
hematopoietic progenitor cells in the colony-forming unit (CFU) assay. 
Imatinib, Nilotinib and Dasatinib treatments significantly reduce CFU growth of 
progenitor CD34+ from CML patients. Nevertheless, a significant increase in CFU 
grow was observed when progenitor CD34+ from CML patients were treated with 
TKIs in the presence of high growth factor cocktail or HS5/SCM. These data indicate 
that not only stroma SCM protects from apoptosis or cell death but also results in a 
higher percentage of cells capable of dividing and repopulating. Moreover, after 14 
days of colony grow, hematopoietic colonies were single plucked from 
methylcellulose and analyzed by Q-RTPCR for the presence of BCR-ABL mRNA, 
revealing that a large proportion of  CD34+ cells remain BCR-ABL positive, after TKI 
treatment, independently from the in vitro applied culture conditions. 
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Figure 12. CD34+ CML progenitor cells are protected from TKI toxicity by 
stroma conditioned media. CD34+ CML progenitor cells (A) cells were treated 
respectively in regular media (RM) (black barrel), or with 50% HS-5/SCM (gray-iron  
barrel), or high grow factor (GF) cocktail (gray-white barrel) with clinical relevant 
concentrations of Imatinib (500nM), Nilotinib (15nM) or Dasatinib (1.2 nM) for 72 
hours. The Figure 12A show that the residual percentage of viable cells after TKI 
treatment, assessed by flow cytometry, was significantly higher in CD34+ cell treated 
in presence of HS5/SCM or high GF cocktail. (B) The induction of overall apoptosis 
(early + late) was significantly reduced in presence of HS5/SCM or high GF cocktail. 
The Figure (C) show that granulocyte-macrophage colony-forming units and 
erythrocyte colony-forming units (CFU) originate from CD34+CML progenitor cells 
was significantly reduced but persistent, after TKI exposition in HS-5/SCM or high GF 
cocktail. The Figure (D) show that a percentage of CFU BCR-ABL positive, after TKI 
treatment, is independently from the in vitro applied culture conditions. Results are 
expressed as mean ± SD from 10 independent experiments. The symbol [*] is for p 
value ≤0.05. 
 
52 
 
 
 
Figure 13: SCM or stroma derived cytokines protects CML CD34+ from TKI-
specific cell death and apoptosis.  
TKI-specific cell death (A) and apoptosis (B) were calculated by subtracting the 
percentage of Annexin-V+/PI+ CML CD34+ cells from un-treated samples to the 
percentage of Annexin-V+/PI+ CML CD34+ cells relative to the specified samples 
treated with TKIs in the presence of RM (black barrel), in media supplemented with 
50% of HS-5/SCM (dark gray barrel) or in media supplemented with high grow factor 
(GF) cocktail (light-gray barrel).  
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Synergistic Effect of JAK2 Inhibitors and TKI to overcome Stroma Related Drug 
Resistance 
We attempted to evaluate if could be possible to reduce the negative effects of 
stroma microenvironment on TKI activity. We suppose that one mechanism could be 
to reduce cell signaling induced by the interaction of a putative soluble factor with its 
specific receptor. In particular, it has been established that cytokines induce 
JAK/STAT pathways through the activation of a specific receptor. Thus, we exploit 
the possibility to down regulate JAK signaling induced by stroma soluble factors, by 
treating K562 cell line with two different JAK2 inhibitors Panobinostat (Pan) or 
Ruxolitinib (Ruxo). In particular, we set-up the following experiments: K562 cells were 
treated with TKI and/or JAK2 inhibitors either in the presence or absence of HS-
5/CM. Apoptosis induction has been monitored after 24hrs by Annexin-V flow 
cytometric test. Panobinostat and Ruxolitinib are not able to reduce cell viability 
(Figure 14 A-B) or induce apoptosis (Figure 14 C-D) in Ph+ cells by their self, as 
expected. Indeed, JAK2 inhibitors do not down-regulate the activity of the oncogene 
BCR-ABL. In contrast, the co-treatment of TKI and JAk2 inhibitors are able to 
significantly reduce cell viability and induce apoptosis in Ph+ cells treated in the 
presence of HS-5/CM. This experiment prove a strong synergistic effect of TKI and 
JAK2 inhibitors to overcome stroma derived TKI resistance. 
It has been recently proved by a carefully conducted study that BM stroma 
conditioned media activates Jak2-Tyk2-Stat3 pathway in CML cells and that knocking 
down JAK signaling by the JAK inhibitor Ruxolitinib (INCB018424), CML cells are 
sensitized to a subsequent Nilotinib treatment. We next sought to determine a 
potential synergistic effect between TKIs and JAK inhibitor Ruxolitinib, by applying a 
dose matrix cell-based assay. In particular, drugs were serially diluted and all 
possible pairs of diluted drug combinations were tested on three independent 
experiments. In particular, K562 cell line was exposed to increasing dose of Imatinib 
or Nilotinib in combination with Ruxolitinib. Cell survival was assessed by 
AnnexinV/PI staining at 72 hours after treatment.  
Ruxolitinib was not effective on K562 cells, demonstrating a modest effect on overall 
viability relative to untreated controls (Fig. 15). However, the combination of Imatinib 
or Nilotinib and Ruxolitinib demonstrated greater toxicity in K562 cells than treatment 
with either TKI alone or Ruxolitinib alone. Next, we tested the effects of drug synergy 
in the presence of HS-5/SCM, with similar results. In particular, combination indices 
(CIs) to determine synergy for the drug combinations (ie, CI<1) were calculated 
according to Chou-Talalay method, which indicated that the combinations were 
synergistic either in the absence or in the presence of HS-5/SCM. Nevertheless, a 
very strong synergism has been achieved in K562 cell line treated with Nilotinib in 
combination with Ruxolitinib in the presence of HS-5/SCM. Moreover, we looked after 
to evaluate the relevance of these findings, also in the modulation of the survival of 
progenitor CD34+ cells from patients with CML. Thus, we co-treated BM CD34+ cells 
with TKIs and Ruxolitinib for 72hrs in the presence or absence of stroma conditioned 
media (HS5/SCM). As shown in Fig. 15A, Ruxolitinib significantly synergize with 
either Imatinib or Nilotinib to reduce cell viability in CD34+ cells derived from CML 
patients, treated in the presence of either HS-5/SCM or high growth factor cocktail. In 
particular, although Ruxolitinib exert a significant cellular effect as single agent in 
CD34+ cells from both CML patients, or healthy donors treated in the presence of 
stroma conditioned media or high growth factor cocktail , the observed increase in 
cell death is significantly lower than the one observed by applying the proposed drug 
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combination. Moreover, the synergistic effect of TKI and Ruxolitinib on the 
modulation of cell viability seems to be selective for CD34+ cells derived from 
patients with CML, since we observed a modest cell death when we treated CD34+ 
cells from healthy donors (CD34+HD cells), irrespective of the concomitant TKI 
treatment. Indeed, Imatinib, Nilotinib and Ruxolitinib each demonstrated a moderate 
ability to impair the formation of CML colonies (CFU) in the presence of HS5/SCM 
(83%, 50% and 61% colonies, respectively, relative to untreated controls). However, 
Imatinib or Nilotinib in combination with Ruxolitinib demonstrated a substantial 
improvement over either Imatinib alone (p<0.0001) or Nilotinib alone (p<0.0001), 
significantly reducing the formation of CML colonies to 6% and 2%, respectively, 
relative to untreated controls. Importantly, Imatinib, Nilotinib, and Ruxolitinib, alone or 
in combination did not significantly impair formation of normal erythroid and myeloid 
colonies. 
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Figure 14: A) Apoptosis induction has been monitored after 24hrs by Annexin-V flow 
cytometric test. Viable of K562 cells treated with 4µM Imatinib and/or JAK2 inhibitors 
either in the absence of HS-5/CM (Black) or in presence of HS-5/CM (Grey). B) 
Viable of K562 cells treated with 4µM Nilotinib and/or JAK2 inhibitors either in the 
absence of HS-5/CM (Black) or in presence of HS-5/CM (Grey). C) Apoptosis of 
K562 cells treated with 4µM Imatinib and/or JAK2 inhibitors either in the absence of 
HS-5/CM (Black) or in presence of HS-5/CM (Grey). D) Apoptosis of K562 cells 
treated with 4µM Imatinib and/or JAK2 inhibitors either in the absence of HS-5/CM 
(Black) or in presence of HS-5/CM (Grey). 
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Figure 15: Very strong synergism of  Imatinib and JAK2 inhibitor Ruxolitinib on 
overcoming stroma derived TKI resistance. K562 cell line was exposed to 
increasing dose of Imatinib (Ima) in combination with increasing doses of Ruxolitinib 
(Ruxo). Cell viability was assessed by AnnexinV/PI staining at 72 hours after 
treatment in RM (A) or in media supplemented with 50% of HS-5/SCM (B). Dose 
matrix summarizes the cell based cytotoxic effect (Z) relative to the drug combination 
(comb) of Imatinib and Ruxolitinib in K562 cells treated in RM (C) or in media 
supplemented with 50% of HS-5/SCM  (D). Cell based cytotoxic effect (Z) for each 
combination dose is reported into the tables C and D; and CI value for each 
combination dose are reported in parenthesis. In particular, based on the CI value, 
we defined, as previously reported, a very strong synergism (dark gray),  strong 
synergism (gray),  synergism (light gray), from moderate synergism to no synergism 
(white).  
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Figure 16: Very strong synergism of Nilotinib and JAK2 inhibitor Ruxolitinib on 
overcoming stroma derived TKI resistance. K562 cell line was exposed to 
increasing dose of Nilotinib (Nilo) in combination (comb) with increasing doses of 
Ruxolitinib (Ruxo). Cell viability was assessed by AnnexinV/PI staining at 72 hours 
after treatment in RM (A) or in media supplemented with 50% of HS-5/SCM (B). 
Dose matrix summarizes the cell based cytotoxic effect (Z) relative to the drug 
combination of Nilotinib and Ruxolitinib in K562 cells treated in RM (C) or in media 
supplemented with 50% of HS-5/SCM  (D). Cell based cytotoxic effect (Z) for each 
combination dose is reported into the tables. CI value for each combination dose are 
reported in parenthesis. In particular, based on the CI value, we defined, as 
previously reported, a very strong synergism (dark gray), strong synergism (gray),  
synergism (light gray), from moderate synergism to no synergism (white). 
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Figure 17. Ruxolitinib synergize with TKI in the elimination of CFU from 
patients with CML.  
CD34+cells derived from either BM of five patients with CML-CP or PB of two 
immobilized HDs, were treated respectively in regular media (RM) (black barrel), or 
with 50% HS-5/SCM (gray-white barrel), or high grow factor (GF) cocktail (gray-iron  
barrel) with clinical relevant concentrations of Imatinib (500nM), Nilotinib (15nM), 
Ruxolitinib (300nM) or drug combination for 72 hours. The Figure (A) show that the 
residual percentage of viable CD34+ CML progenitor cells after TKI treatment or/and 
Ruxolitinib, assessed by flow cytometry, was higher in CD34+ CML progenitor cell 
treated in presence of HS5/SCM or high GF cocktail than RM, but significantly lower 
in cells treated with the drug combination (TKI+ JAK2 inhibitor). Interesting the CFU 
originate from CD34+CML progenitor cells (B) were significantly reduced, but still 
persistents, after Nilotinib or Ruxolitinib exposition in HS-5/SCM or high GF cocktail. 
(B) Data from a clonogenic assay clearly evidenced a significant down-regulation of 
CFU grow when CD34+ CML progenitor cells were treated with the drug combination 
(TKI+JAK2 inhibitor).  
The Figure (C) show that the residual percentage of viable CD34+HD cells exposed 
to HS-5/SCM and treated with Ruxolitinib or drug combination was slightly but 
significantly reduced. (The symbol [*] is for p value ≤0.05). (D) Data from a 
clonogenic assay clearly evidenced that CFU originate from CD34+HD cells still grow 
when treated with clinical concentrations of TKI or/and Ruxolitinib in RM and in 
HS5/SCM.  
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Effects of TKI and JAK2 Inhibitors treatment on CML Progenitor Apoptosis 
To evaluate the synergistic effect of TKI and JAK2 inhibitors on CD34+ progenitor 
cells derived from patients with CML, we treated CML CD34+ cells with 1µM Imatinib, 
2.5nM Dasatinib  and 400nM Nilotinib in the following three different media condition: 
1) serum free media, 2) serum free media supplemented with haemaopoietic pro-
proliferating cytokines (FLT3, SCF, IL3, GCSF and IL6), 3)HS-5/CM. After 72hrs, 
CD34+ cells were analyzed for viability and apoptosis level by Annexin-V/PI assay. 
As shown in Figure 18, the down-regulation of JAK2 signaling by the cotreatment 
with Panobinistat or Ruxolitinib results to be significantly synergic with TKI for the 
reduction of cell viability and induction of apoptosis also if applied on CD34+ 
progenitor cells derived from patients affected by CML. Moreover, we evaluate if the 
CD34+ progenitor cells residual after treatment have clonogenic activity. Indeed, it is 
well known that clonogenic activity is strongly increased in leukemia derived 
progenitor cells.  
Thus, after the described cultures, CD34+ cells were plated in a semi-solid media to 
allow the grow of colony forming unit. In particular, we used methylcellulose-based 
medium, that is widely used to detect and quantify hematopoietic progenitor cells in 
the colony-forming unit (CFU) assay. This approach is suitable for identifying and 
enumerating CFU-E, BFU-E, CFU-G, CFU-M, CFU-GM and CFU-GEMM. After 14 
days, we counted CFU obtained in all conditions. 
Clonogenic activity of CD34+ cells are only modestly reduced after Imatinib 
treatment, whereas the co-treatment of TKI and JAK2 inhibitors is able to significantly 
affect colony growth. 
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Figure 18: CML CD34+ cells were analyzed for viability and apoptosis level by 
Annexin-V/PI assay. CML CD34+ were treated with 1µM Imatinib, 2.5nM Dasatinib  
and 400nM Nilotinib in the following three different media condition: serum free 
media (Blu), serum free media supplemented with haematopoietic pro-proliferating 
cytokines (FLT3, SCF, IL3, GCSF and IL6) (Red), HS-5/CM (Green).  
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Figure 19: Count of CFU growth after 14 days of grow in a semi-solid media. CML 
CD34+ cells treated with 1µM Imatinib, 2.5nM Dasatinib  and 400nM Nilotinib in the 
following three different media condition: serum free media (Blu), serum free media 
supplemented with haemaopoietic pro-proliferating cytokines (FLT3, SCF, IL3, GCSF 
and IL6) (Red), HS-5/CM (Green). After 72hrs of treatment, CD34+ cells were plated 
in a semi-solid media.  
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DISCUSSION  
 
The emergence of drug resistance continues to limit the success in finding a cure for 
hematologic malignancies. CML represents a disease that is initially driven by the 
well-established oncogenic event resulting in the expression of the BCR-ABL fusion 
oncogene. This uniform transforming event common to CML results in an ideal 
disease model to delineate the emergence of drug resistance. Clinical data arising 
from studies targeting BCR-ABL inhibitors indicate that, although BCR-ABL inhibitors 
are very effective in reducing leukemia burden, targeted therapy using a single agent 
does not eliminate minimal residual disease. 
In this work we have shown that resistance to BCR-ABL tyrosin kinase inhibitors is 
related to soluble factors produced by both BM stroma immortalized cell line HS-5 
and CML patient-derived BM stroma cell line. Indeed, we proved that stroma-derived 
microenvironment drug protection is achievable not only by leukemia cell exposition 
to a direct stroma cell contact during TKI treatment, but also by setting up cell culture 
condition implying soluble factors produced by HS-5 or CML patient-derived BM 
stroma cell line. Thus, co-culturing Ph+ K562 cell line with the conditioned media 
derived from HS-5 cell line, CML cells survive to the action of drugs by observing a 
significant increase of viability compared to controls. We also observed the same 
evidence when Ph+ K562 cell line was treated with TKI in the presence of 
conditioned media derived from CML patient BM stroma cell line, that we established 
in our laboratory. Moreover, we demonstrated that the higher cell viability, noticed in 
K562 cells treated with TKI in the presence of stroma conditioned media respect to 
control cell culture condition, is not related to cytokine cell cycle regulation but to a 
significant reduction in apoptosis induction. Indeed, BrdU analysis show a relevant 
accumulation in G0-G1 cell cycle phase of K562 cells treated with TKI, but we 
detected no significant differences in cell cycle phases between K562 cells treated 
with TKI in presence or absence of conditioned media derived from the stroma cell 
line HS-5. To understand whether TKI treatment is able to completely eliminate 
leukemic cells, we conducted a long-term experiment, in which K562 cell viability and 
proliferation were monitored overtime for 14 consecutive day after TKI treatment in 
presence or absence of conditioned media derived from the stroma cell line HS-5. 
We observed that K562 cells treated with TKI in the absence of HS-5/CM cease to 
proliferate and are not more able to encounter cell divisions. In contrast, if K562 cells 
are treated with TKI in the presence of HS-5/CM, after a steady-state of three days 
from the TKI culture addition, cells start to proliferate at the same level of the 
untreated cells. This evidence, strongly suggests that TKIs are not able to completely 
eradicate leukemic cells when stroma derived factor are present in the 
microenviroment.  
Our study may have same clinical relevance, since we also demonstrated in vitro that 
IC50s of the three studied TKI (Imatinib, Nilotinib and Dasatinib) are strongly 
modulated by HS-5/CM. Indeed, we show that we can reduce the Ph+ cell viability 
below the 50% only implying high TKI concentration that are not reasonable achieved 
in vivo in patients. These evidences also confirm what it is coming out from several 
clinical trials applying TKI: target molecular therapy, including Imatinib, induces 
remission in patients with CML but does not eliminate leukemia stem cells, which 
remain a potential source of relapse. Thus, we investigated the activity of two 
different JAK2 inhibitors, Panobinostat and Ruxolitinib, to be synergic with TKI in the 
elimination of CML stem cells. In particular, the first inhibitor Panobinostat is a pan-
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HDAC inhibitor. Histone acetyltransferases and histone deacetylases (HDACs) play a 
central role in modifying the acetylation status of the lysine residues of histone and 
non-histone proteins. Treatment with pan-HDAC inhibitor, such as Panobinostat, 
induces hyperacetylation of histones and non-histone proteins, including heat shock 
protein 90 (Hsp90). Hyperacetylation of Hsp90 inhibits its chaperone function and 
promotes the proteasomal degradation of Hsp90 client proteins, including FLT-3, 
AKT, c-RAF, and JAK2, in leukemia cells [81-82]. Concomitantly, HDAC inhibitor 
treatment has been shown to cause cell cycle growth arrest and apoptosis of 
leukemia cells. In a phase 1 clinical trial, it has been observed that treatment with 
Panobinostat reduced leukemia blast cell numbers in the blood of 7 of 11 patients. 
The second inhibitor Ruxolitinib is a potent and selective JAK1 and JAK2-inhibitor 
(IC50 of 3.3 and 2.8 nmol/L, respectively, in “naked” kinase assays in cell-free in vitro 
systems). It demonstrates modest selectivity against Tyk2 (~6-fold) and ≥ 130-fold 
selectivity against JAK3. Treatment with Ruxolitinib is associated with a dramatic 
decrease in circulating levels of proinflammatory cytokines, IL-6, and tumor necrosis 
factor (TNF)-α, which have been implicated in the pathogenesis of MPNs [83]. 
We demonstrated that either co-treatment with HDACi or JAK2 inhibitor combined 
with TKI effectively induced apoptosis in both K562 cell line and CD34+ progenitor 
quiescent CML cells resistant to elimination by Imatinib, Nilotinib and Dasatinib 
alone, due to BM stroma microenviroment signaling. Thus, HDACi treatment 
represents an effective strategy to target LSC in CML patients receiving tyrosine 
kinase inhibitors. It was very interesting to discover that the synergistic effect of TKI 
and HDACi reduces drug resistance.  
Finally, we attempted to evaluate if the synergic combination of TKI and JAK2 
inhibitors is able to significantly reduce leukemia clonogenic activity in an in vitro 
assay. Thus, we selected CD34+ progenitor cells from BM samples of patients with 
CML. After 72hrs of treatment with TKI and JAK2 inhibitors, residual cells were plated 
in methylcellulose media supplemented with cytokine allowing grow of CFU-E, BFU-
E, CFU-G, CFU-M, CFU-GM and CFU-GEMM. CFUs were encountered after 14 
days and we demonstrated that Imatinib treatment is able to significantly reduce 
colony grow only in the absence of conditioned media from HS-5 or stroma derive 
cytokines with anti-apoptotic and pro-proliferating activity. Moreover, the co-treatment 
of Ph+ CD34+ cells with Imatinib and Panobinostat or Ruxolitinib strongly decrease 
CFU counting in a stroma-independent manner.  
This data strongly suggest that stroma related drug resistance has a relevant role in 
the regulation of TKI responsiveness in patient with CML and that the drug 
concentration needed to eliminate in vitro Ph+ cells in the presence of stroma 
microenviroment is not achievable in vivo clinical trial. Thus, we propose a novel drug 
combination able to be effective in the leukemia eradication: the combined down 
regulation of the BCR/ABL oncogene plus the down-regulation of the signaling 
induced by soluble factors present in the stroma BM microenvironment through 
JAK/STAT pathway may be likely relevant in vivo for the treatment of patients and 
the reduction of relapses. Moreover, since we demonstrated that CML cells are 
protected from TKI activity by soluble factors either derived from immortalized HS-5 
cell line or stroma CML cell lines (data not shown), we performed a quantitative 
evaluation of cytokines present in this two cellular settings. The majority of the 
investigated cytokines, such as M-CSF, SCF, PDGF-bb, IL-6, IL-8, IL-10, IL-12, G-
CSF, GM-CSF, TNF- and VEGF but not the chemotactic factor SDF-1, whereas 
present in significantly higher levels in HS-5/SCM, were also found in CML/SCM. In 
particular, previous studies showed that stroma-mediated drug resistance is due to 
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the increase in the phosphorylation level of Stat3 (Tyr705), thus indicating that the 
stromal protection passes through the activation of this clinically relevant pathway, 
which is known to sustain cell viability in vivo, and to trigger the activation of Jak2–
Tyk2 signaling. Moreover, it was observed that turning off the JAK pathway using a 
JAK inhibitor sensitizes CML cells to Nilotinib treatment in the context of the BM 
microenvironment. Thus, we investigated whether Ruxolitinib differentially synergizes 
with Imatinib, Nilotinib and Dasatinib to overcome stroma related TKI resistance in 
CML cell line or CD34+ progenitor cells from CML patients. Our data indicate that 
Ruxolitinib effectively strongly synergizes with Imatinib, and achieves a very strong 
synergism with second generation TKIs, either Dasatinib or Nilotinib, being able to 
induce apoptosis in both K562 cell line and CD34+ progenitor CML cells resistant to 
the elimination by the single TKI agent, in the presence of BM stroma signaling. 
Indeed, co-treatment of Ph+ CD34+ cells with Ruxolitinib and Imatinib, Nilotinib or 
Dasatinib significantly decreased CFU outgrowth, providing evidence that it is able to 
overcome stromal protection. In contrast with Traer et al., we prove that the JAK 
inhibitor Ruxolitinib, instead the TG101209, used by Traer et al., allows to achieve a 
therapeutic window of drug combination that spear progenitor cells from healthy 
donors or CML patients in MR4. From a clinical point of view, although second 
generation TKIs achieve a deeper and prolonged cytogenetic and molecular 
response rate than Imatinib in patients with CML-CP, the use of TKIs as a single 
agent seems unable to eradicate the disease, despite the increase in MR4.0 rate. 
Our data strongly support the hypothesis that a drug combination of Ruxolitinib and 
second generation TKIs (either Nilotinib or Dasatinib) may be more effective in 
eradicating leukemia rather than the single agent TKI, with minimal toxic effect on 
normal hematopoietic cells. However, the in vivo side effects related to the proposed 
drug combination, need to be determined by a specific clinical trial. The combined 
deep down-regulation of BCR/ABL oncogene plus the down-regulation of the 
signaling induced by the soluble factors present in the stroma BM microenvironment 
through the JAK/STAT pathway may be likely relevant in vivo for the treatment of 
CML patients and may significantly increase the rate of MR4.0, which is the only 
condition that may prelude the decision of treatment interruption. 
We are planning to carry out a secretoma assay. In particular, we will isolate 
acrylamide gel bands derived from running a concentrated preparation of stroma 
conditioned media. Thus, bands will be hydrolyzed and analyzed by mass 
spectrometry. All identified factors will be functionally analyzed.  
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